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ABSTRACT 
 
 
Cervical cancer (CxCa) remains the fourth leading cause of cancer related deaths 
among women worldwide. Cervical cancer is mainly (~ 99.7%) derived from high risk 
Human papillomavirus (HR HPV). HPV E6/E7 are the two main oncoproteins that 
interfere with p53 and pRb (retinoblastoma) cell cycle regulatory proteins and hinder 
their efficacy of controlling cell growth. Additionally, PI3K-Akt is a cell survival 
pathway that is aberrantly expressed in cervical cancer cells. This pathway has a 
profound role in inhibiting mitochondrial intrinsic apoptotic signaling pathway. 
Advanced stage cervical cancer is difficult to treat and patients diagnosed with metastatic 
disease have a poor survival rate. Therefore, there is an urgent need to develop newer 
treatment modalities. Ormeloxifene (ORM) is a non-hormonal, anti-estrogen, oral 
contraceptive for human use. Growing evidences also suggest that ormeloxifene has anti-
cancerous properties in a variety of cancers. Developing nanoformulation of drugs has 
received much attention lately as nanoparticles have site specific targeted drug delivery. 
Nanoparticles have a specific size range that makes them capable of being entrapped and 
accumulated at the tumor site due to its leaky vasculature. As a result of it, drug is 
released from the particle core at a sustained rate; therefore, nanoparticulates offer 
enhanced bioavailability and better therapeutic efficacy. Considering these benefits, we 
engineered ormeloxifene loaded PLGA based novel nanoformulation (PLGA-ORM). In 
this work we validated anti-cancer properties of free ORM and its PLGA based 
nanoformulation. Our set of data showed that ormeloxifene significantly decreased the 
cellular proliferation and clonogenic potential of cervical cancer cells. Ormeloxifene also 
reduced the cellular motility and induced the apoptosis via targeting PI3K-Akt signaling 
in these cells. Furthermore, ormeloxifene modulated the HPV induced oncogenesis in 
Caski cells. Ormeloxifene also showed additive inhibitory effects on cellular proliferation 
and growth when used with radiation. Moreover, our novel PLGA-ORM had a particle 
size range of 100 – 280 nm and also exhibited excellent encapsulation of ormeloxifene in 
to PLGA core. PLGA-ORM was labeled with Coumarin 6 (green fluorescent) dye for its 
uptake studies, where PLGA-ORM internalized in cervical cancer cells in dose, time and 
energy dependent manner via endocytosis pathway. PLGA-ORM showed improved anti-
proliferative/growth properties than free ormeloxifene in cervical cancer cells. When 
utilized in animals (an orthotopic mouse model) both ormeloxifene and PLGA-ORM 
showed great anti-tumorous properties, however PLGA-ORM had improved inhibitory 
effects on tumor growth than free ormeloxifene. To conclude, ormeloxifene and its 
nanoformulation have the potential to be a novel treatment modality for cervical cancer 
which can reduce the overall disease burden and improve patients’ life expectancy.  
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CHAPTER 1.    INTRODUCTION* 
 
 
Statement of the Problem 
 
 
Cervical Cancer 
 
Cervical cancer stands at the fourth rank among most common and deadly 
malignancies in women globally. In the year of 2012, cervical cancer accounted for 
528,000 new cases and 266,000 death incidences around the world. Incidence rates 
remain higher in less developed countries (15.7%) than more developed countries (9.9%) 
mainly in Eastern (42.7%), Middle (30.6%) and South Africa (31.5%) [1]. In developing 
countries this is the major cause in women who are at reproductive age and the reason 
being is less awareness and availability of screening modalities [2-4]. 
 
 
Cervical Cancer and Human Papillomavirus 
 
Cervical cancer is primarily associated with the high risk Human Papillomavirus 
(HPV) infection [5-9]. HPV’s are circular, double stranded DNA viruses consisting of 
about 8000 base pairs (Figure 1-1) [10-14] and are the most common type of sexually 
transmitted virus infection [15-17]. Upon the classification, there are more than 100 well 
known human papillomaviruses which are further divided in to two categories – High 
Risk and Low Risk (Figure 1-2)  [18]. Persistent infection of any of these 13 High risk 
HPV’s (HVP 16, 18, 31, 33, 35, 39,45, 51, 52, 56, 59 and 66) can result in the 
progression of cervical cancer [19, 20] while Low Risk HPVs such as 2, 4, 5, 10 and 15 
are known to cause warts [21-23]. HPV 16 and 18 are the most shared type of HPVs and 
account for about 70 % of invasive cervical cancer cases [24]. Like other cancers, 
cervical cancer also has various changes at genetic level, loss of 11q and gain of 3q are a 
common characteristic change in HPV positive cells [25, 26]. HPV infection can either 
be latent or active [27], if the virus completes its life cycle then it is a latent infection 
[28]. When a virus completes the life cycle, huge production of viral progeny is desired 
which is carried out by the HPV replication protein E1 and mainly E2 [29]. E2 is the 
major player in HPV life cycle which controls the expression of other viral genes [30]. 
When the virus starts integrating in to host cell genome, this event deregulates the E2 
replication protein, this deregulation of E2 eventually leads to the increased expression of 
E6 and E7 as they are repressed by E2 [30]. During the life cycle, E6 and E7 are 
expressed at the lower epithelial layer of cells where these two proteins facilitate cells as 
they move from G1 cell cycle phase to S phase which is the synthesis phase, thus, 
expression of HPV E6 and E7 results in elevated rate of cell proliferation [31-33]. Capsid 
 
 
----------------------------- 
* Adapted with permission. Khan, S., et al., Nanoparticle formulation of ormeloxifene for 
pancreatic cancer. Biomaterials, 2015. 53: p. 731-743.  
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Figure 1-1. Diagram shows the structure of HPV. 
Modified with permission. Yugawa, T. and T. Kiyono, Molecular mechanisms of cervical 
carcinogenesis by high‐risk human papillomaviruses: novel functions of E6 and E7 
oncoproteins. Reviews in medical virology, 2009. 19(2): p. 97-113.  
 
 
 
 
 
Figure 1-2. Diagram shows the general classification of HPVs. 
  
  
3 
proteins L1 and L2 are expressed at the upper epithelial layer cells along with E4 to 
gather and provide structure to the progenies [28]. Malignant cervical cancer cells 
specifically express two viral oncoproteins HPV E6 and E7 [34]. HPV E6 and E7 are 
known to cause genomic alterations resulting in gain or loss of function of genes in 
various cancers including cervical cancer [25, 26]. E6 and E7 disturb the functions of p53 
(protein 53) and Rb (Retinoblastoma protein), two tumor suppressor proteins. Both the 
proteins regulate cell cycle progression and excessive cell proliferation. The E6 binds to 
p53 and degrades it by proteosomal degradation [35, 36]. Whereas the E7 oncoprotein 
binds to Rb and degrades it which leads to the induction of cell growth and gene 
promoting DNA synthesis [37, 38]. Rb specifically (pRb) binds to the E2F which is 
transcription factor, and prevents E2F from interacting with other cyclins and cyclin 
dependent kinases, thus, inhibiting proliferation. But upon the binding of E7, pRB cannot 
perform this preventive action on E2F which allows E2F to interact with other cyclins 
and thus, promotes cell proliferation and cell cycle progression (Figure 1-3) [39-42]. 
PTPN 13 is a nonreceptor phosphatase that also gets degraded by HPV E6 upon its 
binding [43]. 
 
 
Other Risk Factors 
 
Though HPV is the most common factor of cervical cancer yet alone it is not 
enough to develop cervical cancer and requires other risk factors such as smoking, 
multiple sexual partners, and first intercourse at young age, use of oral contraceptives and 
low socioeconomic status [44-47].  Some case control studies show an establishment 
between the use of oral contraception and development of cervical cancer but the studies 
are of poor quality and data is inconsistent and insignificant as the confidence interval 
values (CIs) were wide [48-50]. Also, there is a good number of studies which report that 
association between oral contraceptive and HPV infection/ cervical cancer is just due to 
the reason that women already being on one type of birth control strategy are very likely 
not to use other protection system, thus are more prone to get infection via sexual 
contacts [51-54]. Among females, cigarette smoking has two times higher risk of having 
cervical cancer than those who do not smoke [16], even the secondary exposure to 
cigarette smoke has been associated with the incidences of cervical cancer [55, 56]. A 
well-known cigarette smoke carcinogen, BaP (Banzo[a]pyrene increases the expression 
levels of HPV oncoproteins E6 and E7 in cervical cancer cells [57]. There are reports that 
suggest that cigarette smoke residuals are found in the mucus sample of women who 
smoke [58-60]. Epidemiology of cervical cancer suggests that having multiple sexual 
partners and young age at first sexual intercourse, increases the risk for HPV infection 
and development of cervical cancer among women [61, 62]. One other risk factor that  
also contributes toward developing cervical cancer, is elevated hormones especially 
estrogen and progesterone during the pregnancies which effects the HPV regulation in the 
system [63]. There is a link between estrogen receptor α and cervical cancer 
tumorigenesis. Estrogen receptor α promotes tumor development in HPV transgenic 
cervical cancer mice model where as mice that were given no estrogen receptor showed  
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Figure 1-3. A schematic of cell cycle progression. 
Modified with permission. Dehay, C. and H. Kennedy, Cell-cycle control and cortical 
development. Nature Reviews Neuroscience, 2007. 8(6): p. 438-450. 
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no symptoms of developing tumors. Therefore, molecules that can target estrogen 
receptor, hold great promises to become anti-cervical cancer agents [64]. 
 
 
Other Oncogenic Signaling in Cervical Cancer 
 
It is known that HPV infection changes or modulates different signaling pathways 
which eventually leads to the induction of cervical cancer [65].  HPV signaling needs few 
other different pathways in order to promote cell survival and proliferation namely Ras, 
Notch receptor, Growth factor receptor and PI3KCA [66-69]. PI3K-Akt signaling gets 
modulated and activated by HPV E6 and E7 [70, 71]. PI3K-Akt is a cell survival pathway 
which is responsible for many cellular functions such as cell proliferation, cell survival 
and cell cycle progression in variety of cancers [72-74]. PI3K-Akt is one of the most 
aberrantly expressed pathways in cervical cancer cells [75-78]. Akt becomes 
phosphorylated at serine and threonine residuals by the overexpression of PI3K [79] and 
thus, gets activated for the further initiation of apoptosis cascade [80]. Human cervical 
cancer tissue samples express the increased levels of pAkt [81], therefore, PI3K-Akt 
signaling pathway has gained much attention for the therapeutic aspects in cervical 
cancer [82].  
 
 
Current Available Treatments and Their Limitations 
 
In many developed countries Pap Smear Screening (Pap test) is available to detect 
the pre-cancerous changes at the cervix which has greatly reduced the incidences 
(occurrence) of cervical cancer as the pre-cancerous lesions can be detected and followed 
up by treatments,  [54] but it is also reported that Pap screening results in almost about 
20% of false negative results [83]. HPV testing is also available for the detection of high 
risk HPVs alone or in the combination with Pap test [84]. Being a viral disease, there are 
many vaccines generated and available too for prevention purposes of cervical cancer 
[85]. Gardasil and Cervarix are two approved vaccines that are in human use and provide 
100% protection against HPV 16 and 18 which has been reported to last up to 8-9 years 
[86-88]. Current treatment modalities available for the management of cervical cancer are 
disease stage dependent; early stage patients are mainly advised surgery or radiotherapy 
[89, 90] whereas late stages of cervical cancer are tackled by radiation along with 
cisplatin based chemotherapy [91].    
 
Although cervical cancer is highly preventable, yet the mortality rate remains high 
and reasons are the limitations and drawbacks of current prevention and treatment 
modalities. The available vaccines for preventing the disease have age limitation. They 
are suggested to use between the ages of 13 to 26 but vaccination can be started as early 
as at age 11 [92]. The other treatment methods such as surgery, radiation and 
chemotherapy have their own adverse effects. Patients often suffer from weakness, 
fatigue, weight loss, appetite loss and infertility. Despite of having many current 
available treatment choices, 100% success rate is not guaranteed and usual recurrence 
time is 2 years [93-95].  
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Repurposing of Drugs 
 
According to an estimate it takes almost 15-20 years and about $800 million USD 
of cost to get a new drug entity to the market [96, 97] and that too comes with constraint 
of Food and Drug Administration (FDA) as FDA only approves less than 30 new 
compounds every year [97, 98]. All these obstacles make it difficult to discover new 
drugs for cancer management [99]. In order to overcome this issue one proposed 
mechanism is to reuse the drugs that are already in market for other uses [100]. This 
newer approach is called “drug repositioning” or “drug repurposing” or “drug re-
profiling” or “therapeutic switching” [101]. There are various molecules that have been 
repurposed for cancer treatment. Some of the illustrations given here are recent studies 
with metformin on various cancer treatments [102-104] which traditionally is an anti-
diabetic molecule [105]. Aspirin which is a very well know analgesic has been 
established as a potent anti-cancer molecule for metastatic lung cancer [106], as well as 
brain, esophageal, pancreatic and gastrointestinal [107], and it is also reported that long 
term (up to 5 years) daily consumption of aspirin can reduce the risk of developing 
colorectal cancer [108]. Another very well described example of drug-repositioning is 
rapamycin which is a known inhibitor of mTOR pathway which is highly expressed in 
various cancers [109]. Therefore, rapamycin has been studied for its anti-cancer 
properties and it shows brilliant anti-tumorous activities for myeloid leukemia [110] and 
myelogenous leukemia [111]. 
 
 
Ormeloxifene 
 
Ormeloxifene (Centchroman), C30H35O3N.HCl, (Figure 1-4) [112] is a non-
steroidal, non-hormonal anti-estrogen oral contraceptive for human use that is taken once 
per week and was first synthesized by Central Drug Research Institute, India [113]. 
Ormeloxifene is a SERM (Selective Estrogen Receptor Modulator) which inhibits 
estrogen receptors (ER) in uterus, cervix, ovary and breast while promoting these 
receptors in other organs such as bones [114, 115]. Ormeloxifene is a crystalline 
molecule, white in color and has a molecular weight of 493.5Da. It is insoluble in water 
but soluble in ethanol, methanol, acetone and chloroform (organic solvents) [114, 116]. 
Ormeloxifene is stable at room temperature and 4°C with maintaining its biological 
activities [117]. Ormeloxifene showed excellent pharmacokinetic and pharmacodynamics 
properties with low binding affinity toward human plasma proteins and no affinity toward 
steroids present in the body [118-123]. Ormeloxifene is generally metabolized by liver 
but if high amounts of the drug are provided, traces can be found in spleen, lungs and 
uterus [124, 125]. In animals (adult female rats) the half-life of the drug is about 24 hours 
when administered orally using 12.5 mg/kg of ormeloxifene [124]. While in humans 
(adult healthy females) the half-life of ormeloxifene is around 168 hours when 
administered orally with either 30 mg or 60 mg of dose [126]. Recent studies have 
repurposed ormeloxifene for its anti-cancer properties namely; it inhibits cell 
proliferation/growth and motility, moreover, it was reported to block cell cycle and 
induce apoptosis [127]. Previous studies suggest that ormeloxifene has strong anti-breast  
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Figure 1-4. Structure of ormeloxifene. 
Modified with permission. Kumar, R., et al., Selective estrogen receptor modulators 
regulate stromal proliferation in human benign prostatic hyperplasia by multiple 
beneficial mechanisms—action of two new agents. Investigational new drugs, 2012. 
30(2): p. 582-593. 
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cancer [113] and anti-head and neck cancer properties [128]. Ormeloxifene has been used 
as an anti-neoplastic agent in MCF-7/ MDA MB-231 Estrogen Receptor (ER±ve) Human  
Breast Cancer Cells (HBCCs) [129, 130]. Moreover, ormeloxifene works excellently in 
combinational therapies as well with curcumin or resveratrol [131] and with glycine soya 
[132] against breast cancer. Results from these studies suggest that ormeloxifene works 
with both ER dependent and ER independent mechanisms and also it seems to work 
through various different other pathways such as PI3K-Akt, STAT3 and SHH. Another 
study shows that not only solid tumors but ormeloxifene also targets hematological 
tumors such as chronic myeloid leukemia [133]. Our group has recently published that 
ormeloxifene also has potent anti-pancreatic [134] and anti-ovarian [135] cancers 
properties.  
 
 
Nanomedicine 
 
Nanotechnology is a newer therapeutic approach with great success over 
traditional chemotherapy [136-139]. Nanoparticles have a suggested size range of 100-
300 nm [138, 140]. Size is the most important consideration while designing a 
nanomedicine as it decides the fate of nanoparticle’s cellular uptake [141-143] and 
biodistribution [144-146]. Particle size that is lesser than 5-10 nm is rapidly cleared by 
kidneys [146, 147]. Also, particle size that is around 15 µm tends to accumulate in liver 
and spleen [148-150]. Nanoparticle formulations provide targeted delivery of drugs along 
with improved bioavailability in the system, thus, they are an attractive tool for evolving 
newer treatment patterns for cancer [151-154]. Free drugs are not site-specific when 
delivered to the body while modern methodology of nano-carriers facilitates the site-
specific targeted delivery of drugs [155-157]. Due to the leaky vasculature of the tumor 
and enhanced permeation and retention (EPR) effect (Figure 1-5) [157-159], nanodrugs 
can specifically be entrapped and accumulated into tumors [160-162]. Initial nanoparticle 
formation was limited to liposomal and polymer based nanomaterial which is also called 
first generation nanoparticles [163]. The first liposomal based nanoformulation that made 
to the market was doxorubicin loaded liposomal nanoformulation called Doxil which 
showed better therapeutic effects than free doxorubicin [164-166]. Polymer based 
nanoformulation have also been studied [167, 168], for illustration, Poly(lactide-co-
glycolide) (PLGA) is an FDA-approved biodegradable and biocompatible polymer 
employed for controlled drug delivery applications including anti-cancer drug delivery 
[169-175]. Besides our research group, other investigators have also shown that using 
PLGA nanoparticles to deliver chemotherapeutic drugs results in significant 
improvement in inhibition of tumor burden in a wide variety of cancer models [176-181]. 
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Figure 1-5. Diagram shows EPR (enhanced permeation and retention) effect.  
Modified with permission. Regehly, M., Photoinduced transfer processes in complex 
carrier systems for photodynamic therapy. 2008, Humboldt-Universität zu Berlin, 
Mathematisch-Naturwissenschaftliche Fakultät I.  
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CHAPTER 2.    EVALUATION OF ANTI-PROLIFERATIVE ACTIVITY OF 
ORMELOXIFENE IN CERVICAL CANCER CELLS 
 
 
Materials and Methods 
 
 
Cell Culture 
 
All cells (Caski and SiHa (HPV positive), C33A and HT3 (HPV negative)) were 
obtained from ATCC. SiHa and C33A were cultured in DMEM medium supplemented 
with 4500 mg/L glucose, 4.00 mM L- Glutamine, 10% heat inactivated FBS (Atlantic 
Biologicals, Lawrenceville, G.A.), 1% (5 ml) sodium pyruvate, 1% (5ml) nonessential 
amino acids and 1% (5 ml) 1× antibiotic/ antimycotic (Sigma, St. Louis MO). Caski cells 
were maintained in RPMI medium containing 2.05 mM L-Glutamine, 10% heat 
inactivated FBS and 1% (5 ml) 1× antibiotic/antimycotic. HT3 cells were grown in 
McCoy’s 5A medium accommodated with L- Glutamine, 10% heat inactivated FBS and 
1% (5 ml) antibiotic/antimycotic. All cells were incubated at 37º C in a humidified 
atmosphere of 5% CO2.  
 
 
Cell Proliferation Assays 
 
We utilized four different cervical cancer cell lines for proliferation 
measurements, Caski, SiHa, C33A and HT3 [129]. All cells were seeded at 5000 cells in 
100 µL media per well in 96-well plates and allowed to attach overnight. Following day, 
all 4 cervical cancer cell lines were treated with different micromolar concentrations (10 
µM to 30 µM) of ormeloxifene (India). Ormeloxifene was dissolved in ETOH, diluted in 
tissue culture medium and then added to 96-well plates for 48 hours incubation. After 48 
hours the CellTiter96 Aqueous One Solution (Promega, Madison, WI) was added to 96-
well plates (20 µl/well), and the plates were incubated  at 37º C for 2 hours and  
absorbency was measured at 490 nm using a spectrophometer. Three readings were 
obtained for each plate and proliferation results were normalized to control wells treated 
with vehicle control ETOH. The experiment was performed three individual times in 
duplicate each time.  
 
 
Colony Forming Assays  
 
All cervical cancer cells were seeded at 200 cells in 2 mL/well (Caski, SiHa and 
C33A) and 500 cells in 2 mL/well (HT3) in 6 well plates and allowed to adhere 
overnight. The following day, fresh media containing different micromolar 
concentrations (2.5 µM to 10 µM) of ormeloxifene was added to the cells and cells were 
maintained for next 14 days. On the 14th day cells were washed, fixed in cold methanol 
and stained with hematoxylin (Thermo Fisher). Visible colonies (~50 cells) were counted 
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and presented as compared to the vehicle (ETOH) control. Each experiment was done in 
duplicate and repeated 3 times. 
 
 
Real Time Cell Proliferation Kinetic Assay through xCELLigence System 
 
To determine the effect of ormeloxifene on real time cellular proliferation/growth, 
the xCELLigence system was used as described earlier [134]. xCELLigence system 
measures the cellular events (cell proliferation, migration and invasion) in real time as it 
is an electrical impedance-based method. In this experiment, plates (E plate VIEW 16, 
ACEA Biosciences) were pre-incubated with 30 µL media for 30 min at 37º C and read 
for background measurement. Afterwards, both Caski and SiHa cells were plated at 8 × 
103/chamber in 100 µL drug (20 µM ormeloxifene) containing media for cell 
proliferation. Chamber plates were then incubated in xCELLigence instrument 
chamber/unit at 37° C with 5% CO2 for real time cell proliferation. The experiment was 
performed two times. 
 
Statistical Methods 
 
Statistical analysis was determined by using an unpaired, two tailed student’s t-
test. The results were considered significant if P< 0.05. All graphs were generated using 
GraphPad Prism5 software.  
 
 
Results 
 
 
Ormeloxifene Treatment Inhibits Cellular Proliferation of Various Cervical Cancer 
Cells 
 
To determine the effect of Ormeloxifene on cell growth of various cervical cancer 
cells, we performed cell proliferation (MTS) assays with Caski and SiHa (HPV positive) 
and C33A and HT3 (HPV negative). Cells were treated with ormeloxifene at different 
micro-molar ranges for 48 hours. All four cells lines showed a significant decrease in a 
dose- dependent manner and a drastic inhibitory effect was found between 20 µm and 30 
µm doses (Figure 2-1, Figure 2-2, Figure 2-3 and Figure 2-4).  
 
 
Ormeloxifene Treatment Inhibits Clonogenic Potential of Various Cervical Cancer 
Cells 
 
Colony forming ability is an essential property of cancerous cells toward 
developing the tumor. Thus, we assessed colony forming assays to determine the long 
term effect of ormeloxifene on cervical cancer cells. Ormeloxifene showed a significant  
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Figure 2-1. Ormeloxifene decreased cellular proliferation of Caski cells.  
Cells were treated with ormeloxifene (10, 20, 25, and 30 µM) for 48 hrs and MTS 
method was used to determine proliferation and absorbance was measured at 490 nm. 
Results were normalized to the vehicle control (ETOH). Error bars show SEM, n=3. 
*p<0.05. 
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Figure 2-2. Ormeloxifene decreased cellular proliferation of SiHa cells. 
Cells were treated with ormeloxifene (10, 20, 25, and 30 µM) for 48 hrs and MTS 
method was used to determine proliferation and absorbance was measured at 490 nm. 
Results were normalized to the vehicle control (ETOH). Error bars show SEM, n=3. 
*p<0.05. 
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Figure 2-3. Ormeloxifene decreased cellular proliferation of C33A cells. 
Cells were treated with ormeloxifene (10, 20, 25, and 30 µM) for 48 hrs and MTS 
method was used to determine proliferation and absorbance was measured at 490 nm. 
Results were normalized to the vehicle control (ETOH). Error bars show SEM, n=3. 
*p<0.05. 
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Figure 2-4. Ormeloxifene decreased cellular proliferation of HT3 cells. 
Cells were treated with ormeloxifene (10, 20, 25, and 30 µM) for 48 hrs and MTS 
method was used to determine proliferation and absorbance was measured at 490 nm. 
Results were normalized to the vehicle control (ETOH). Error bars show SEM, n=3. 
*p<0.05. 
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effect on clonogenic potential of all tested cervical cancer cell lines in a dose dependent 
manner (Figure 2-5, Figure 2-6, Figure 2-7, Figure 2-8, Figure 2-9, Figure 2-10, 
Figure 2-11 and Figure 2-12). 
 
 
Real Time Growth Kinetics 
 
We performed a real time growth kinetic study using xCELLigence system to 
confirm ormeloxifene’s effect on proliferation of Caski and SiHa cells. The study was 
conducted up to 160 hours and results were similar to MTS results. Ormeloxifene at 20 
mM markedly decreased the cellular proliferation of both Caski and SiHa cells as 
compared to vehicle control ETOH (Figure 2-13 and Figure 2-14). 
 
 
 
 
 
 
Figure 2-5. Ormeloxifene inhibited clonogenic potential of Caski cells. 
Qualitative representation of inhibited clonogenecity of cells. Images were taken at 200X. 
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Figure 2-6. Bar graph showing that Ormeloxifene inhibited clonogenic potential 
of Caski cells. 
Cells showed inhibited colony forming ability after 14 days of ormeloxifene treatment. 
Results were normalized to the ETOH control. Error bars show SEM, n=3. *p<0.05. 
 
 
 
 
 
Figure 2-7. Ormeloxifene inhibited clonogenic potential of SiHa cells. 
Qualitative representation of inhibited clonogenecity of cells. Images were taken at 200X.  
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Figure 2-8. Bar graph showing that Ormeloxifene inhibited clonogenic potential 
of SiHa cells. 
Cells showed inhibited colony forming ability after 14 days of ormeloxifene treatment. 
Results were normalized to the ETOH control. Error bars show SEM, n=3. *p<0.05. 
 
 
 
 
 
Figure 2-9. Ormeloxifene inhibited clonogenic potential of C33A cells. 
Qualitative representation of inhibited clonogenecity of cells. Images were taken at 200X. 
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Figure 2-10. Bar graph showing that Ormeloxifene inhibited clonogenic potential 
of C33A cells. 
Cells showed inhibited colony forming ability after 14 days of ormeloxifene treatment. 
Results were normalized to the ETOH control. Error bars show SEM, n=3. *p<0.05. 
 
 
 
 
 
Figure 2-11. Ormeloxifene inhibited clonogenic potential of HT3 cells. 
Qualitative representation of inhibited clonogenecity of cells. Images were taken at 200X. 
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Figure 2-12. Bar graph showing that Ormeloxifene inhibited clonogenic potential 
of HT3 cells. 
Cells showed inhibited colony forming ability after 14 days of ormeloxifene treatment. 
Results were normalized to the ETOH control. Error bars show SEM, n=3. *p<0.05. 
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Figure 2-13. Ormeloxifene inhibited growth of Caski cells in real time. 
Cells were exposed to ormeloxifene treatment and measured for real time growth 
kinetics. 
 
 
 
 
 
Figure 2-14. Ormeloxifene inhibited growth of SiHa cells in real time. 
Cells were exposed to ormeloxifene treatment and measured for real time growth 
kinetics. 
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CHAPTER 3.    DETERMINATION OF ANTI-MOTILITY PROPERTITES OF 
ORMELOXIFENE IN CERVICAL CANCER CELLS 
 
 
Materials and Methods  
 
 
Agarose Bead Assay 
 
To determine the effects of ormeloxifene on cellular motility of cervical cancer 
cells we performed agarose bead assay as performed previously in our lab [182]. For this 
experiment, 6-well plates were pre-coated with BSA-fibronectin. Cells (1X105) were 
trypsinized and mixed into a 0.2% low melting point agarose solution. About 30 µL of 
cells/agarose suspension was then plated onto fibronectin/bovine serum albumin coated 
plates. The agarose-beaded plates were placed at 4º C for 10 min to set the agrose beads. 
Complete growth medium was slowly added from the edges of the wells so that beads 
were not disturbed and completely covered, and then plates were placed into a cell 
culture incubator at 37º C with 5% CO2 . At 0, 12, 24 and 48 hrs the plates were removed 
from the incubator and photographed under a phase-contrast microscope.  
 
 
Boyden Chamber Cell Migration Assay 
 
Cell migration assay was performed in a 96 well format HTS transwell plate from 
Corning. Both Caski and SiHa cells were serum starved for overnight and next day plated 
at 30,000 cells/well density in upper chambers containing 100 µL serum free culture 
medium with different (10, 20 and 25 µM) concentrations of ormeloxifene treatment and 
allowed to migrate towards FBS gradient to lower chamber with 10% FBS for next 24 
hours. At the end of indicated time cells were fixed with 4% paraformaldehyde prepared 
in PBS for 30 min at room temperature and stained with crystal violet for next 30 min. 
Plates were then washed with running water to remove any excess staining. Cells in the 
upper chamber were completely removed by cotton swab while wet and plates were air 
dried overnight, next day, migrated cells were observed/ imaged by using light 
microscope at 100X magnification.  
 
 
Boyden Chamber Matrigel Cell Invasion Assay  
 
For invasion assay, we used BD Biocoat Matrigel Invasion Chambers 24 
transwell format (BD Biosciences). Invasion chambers/inserts were rehydrated with 500 
µL serum free culture medium for 2 hours at 37º C. After 2 hours, 30,000 serum starved 
cells (cells were serum starved for overnight), in 500 µL media, were plated in upper 
chamber/insert. The lower wells were also filled up with 500 µL serum free media and 
chamber containing plates were incubated at 37º C for next 24 hours. Ormeloxifene 
treatment at 10, 20 and 25 µM concentrations in 500 µL serum free media was given to 
the upper chambers next morning and serum free media in lower wells was replaced with 
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10% FBS containing media. Cells were now allowed to invade across the matrigel 
towards FBS gradient in the lower chamber for next 24 hours. At the end of given time 
point, cells were fixed with 4% paraformaldehyde for 30 min at room temperature, 
stained with crystal violet for another 30 min, washed with running water, and air dried. 
Cells at the bottom side of chamber/insert (invaded cells) were imaged at 100X 
magnification by using a light microscope. 
 
 
Real Time Migration and Invasion Assays through xCELLigence System 
 
The xCELLigence system was used for real time migration assessment of Caski 
and SiHa cells. 16 chamber plates (CIM plate 16, ACEA Biosciences) were utilized for 
this assay and the upper chambers were pre-incubated with 30 µL serum free media for 
30 min at 37º C and the background reading was recorded. Next, Caski and SiHa cells 
were plated at 3 × 104 per chamber with ormeloxifene (10, 20 and 25 µM) and its vehicle 
control ETOH treatments in 100 µL serum free media. The bottom wells were provided 
with 160 µL of 10% FBS media. Cells were allowed to settle for 30 min at room 
temperature before plates were incubated in xCELLigence instrument chamber/unit at 
37° C with 5% CO2. In invasion assay before pre-incubation, the upper chambers were 
coated with 800 µg/mL matrigel (80 µL matrigel + 1920 µL serum free media) for 4 
hours at 37º C. Each experiment was done twice. 
 
 
Statistical Methods 
 
All graphs were generated using GraphPad Prism5 software. 
 
 
Results 
 
Ormeloxifene inhibited cellular migration and invasion of cervical cancer cells. In 
order to analyze the metastatic properties of cervical cancer cells after ormeloxifene 
treatment, we performed agarose bead assay (Figure 3-1 and Figure 3-2), cell migration 
(Figure 3-3 and Figure 3-4) and invasion assays (Figure 3-5 and Figure 3-6) using 
Boyden chamber migration and Boyden chamber matrigel invasion assay. Both Caski and 
SiHa cells showed an inhibition of motility/migration and invasion with an increase in 
ormeloxifene concentration. A real time kinetic assessment for migration (Figure 3-7 and 
Figure 3-8) and invasion (Figure 3-9 and Figure 3-10) was also performed using 
xCELLigence system to confirm ormeloxifene’s effect on metastasis of Caski and SiHa 
cells, and results were consistence with Boyden chamber assay. Furthermore, migratory 
ability of cells was analyzed by using agarose bead and wound healing assays. 
Ormeloxifene treatment again showed an inhibition of migration in dose and time 
dependent manner in both cells. 
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Figure 3-1. Ormeloxifene decreased cellular motility of Caski cells confirmed 
through agarose bead assay. 
Cells were treated with ormeloxifene up to 48 hours and images were taken at 100X.  
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Figure 3-2. Ormeloxifene decreased cellular motility of SiHa cells confirmed 
through agarose bead assay. 
Cells were treated with ormeloxifene up to 48 hours and images were taken at 100X.  
 
 
 
 
 
Figure 3-3. Ormeloxifene decreased cellular migration of Caski cells confirmed 
through Boyden chamber migration assay. 
Cells were treated with ormeloxifene for 24 hours and images were taken at 100X.  
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Figure 3-4. Ormeloxifene decreased cellular migration of SiHa cells confirmed 
through Boyden chamber migration assay. 
Cells were treated with ormeloxifene for 24 hours and images were taken at 100X.  
 
 
 
 
 
Figure 3-5. Ormeloxifene decreased cellular invasion of Caski cells confirmed 
through Boyden chamber matrigel invasion assay. 
Cells were treated with ormeloxifene for 24 hours and images were taken at 100X. 
 
 
 
 
 
Figure 3-6. Ormeloxifene decreased cellular invasion of SiHa cells confirmed 
through Boyden chamber matrigel invasion assay. 
Cells were treated with ormeloxifene for 24 hours and images were taken at 100X.  
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Figure 3-7. Ormeloxifene inhibited migration of Caski cells in real time. 
Cells were exposed to ormeloxifene treatment and measured for real time migration 
kinetics. 
 
 
 
 
 
Figure 3-8. Ormeloxifene inhibited migration of SiHa cells in real time. 
Cells were exposed to ormeloxifene treatment and measured for real time migration 
kinetics. 
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Figure 3-9. Ormeloxifene inhibited invasion of Caski cells in real time. 
Cells were exposed to ormeloxifene treatment and measured for real time invasion 
kinetics. 
 
 
 
 
 
Figure 3-10. Ormeloxifene inhibited invasion of SiHa cells in real time. 
Cells were exposed to ormeloxifene treatment and measured for real time invasion 
kinetics. 
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CHAPTER 4.    ASSESSMENT OF APOPTOSIS INDUCING ABILITY OF 
ORMELOXIFENE IN CERVICAL CANCER CELLS 
 
 
Materials and Methods  
 
 
Morphology Visualization with Phase Contrast Microscopy   
 
Both cervical cancer cell lines were plated at 1X106 per 100 mm dish and allowed 
to adhere for overnight. Next day, cells were treated with a range of ormeloxifene 
concentrations (10, 20 and 25 μm) for 24 hours. At the end point cells were washed with 
PBS and images were taken by using phase contrast microscopy at 200X.  
 
 
Mitochondrial Membrane Potential 
 
Reduction in mitochondrial membrane potential is the first and an important event 
of intrinsic mitochondrial apoptotic cascade [183, 184]. Tetramethyl rhodamine ethyl 
ester (TMRE) (Invitrogen) is an orange colored, positively charged dye that 
premeabilizes through the mitochondrial membrane and sequesters into the healthy and 
active mitochondria; thus, it is a widely used marker for mitochondrial membrane 
potential [185]. Caski and SiHa cervical cancer cells at 1X106/plate were plated, allowed 
to attach overnight and exposed to ormeloxifene treatment for 24 hours. At the indicated 
time, cells were washed with PBS, incubated with 2 mL phenol red free medium 
containing 50 nM TMRE at 37° C for 20 minutes, washed twice with PBS and supplied 
with phenol red free medium and imaged using an Olympus microscope for the 
qualitative assessment at 200X. After imaging, cells were washed with PBS, trypsinized 
and analyzed with Accuri C6 flow cytometer in FL2 channel for the quantitative 
measurement.  
 
 
Cell Cycle Analysis 
 
Telford method is a widely used method to detect different phases of cell cycle 
[186]. Caski and SiHa cells were plated in 100 mm dish at the density of 1X106/plate and 
allowed to adhere overnight. Next day, cells were exposed to ormeloxifene treatment at 
10 and 20 µM concentration for 24 hours. After 24 hours, cells were trypsinized, washed 
twice with PBS, fixed with 70% ice cold ETOH and saved at -20° C until further used. 
Cells were stained with Propidium Iodide solution (Sigma-Aldrich, St. Louis, MO) 50 µg 
in 1 mL Telford reagent at 1 mL for 1X106 cells for 4 hours at 4° C in the dark and 
analyzed by Accuri C6 (BD Biosciences) flow cytometer in FL2 channel of red 
fluorescence.  
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Annexin V- 7AAD Staining 
 
Annexin V labels the early apoptotic cells by binding to phosphatidylserine which 
becomes exposed at the outside of the cell membrane as cells undergo apoptosis; thus, it 
is a marker of early apoptosis [187] where as 7AAD is a marker of dead cells [188]. To 
assess the induction of apoptosis, Caski and SiHa cervical cancer cells were plated 
(1X106/plate) and allowed to attach overnight. Next morning, cells were treated with 
different concentrations of ormeloxifene for 24 hours; both floaters and adherent cells 
were collected, washed twice with PBS and stained with Annexin V and 7AAD (BD 
Biosciences, San Diego, CA), 5 µL of each/100 µL of cell suspension for 20 min in the 
dark at room temperature. After the incubation, cells were analyzed with Accuri C6 flow 
cytometer in FL2 channel.  
 
 
Reactive Oxygen Species (ROS) 
 
Both Caski and SiHa cervical cancer cells were plated at 1X106/100 mm dish and 
allowed to adhere overnight. Next morning, cells were exposed to 25 µM concentration 
of ormeloxifene for 24 hours. After 24 hours cell were washed with PBS, trypsinized and 
centrifuged at 1000 RPM for 5 min. The final cell pellet was resuspended in 1 mL of PBS 
containing 20 µM DCFH-DA stain (a dye that is widely used to detect generation of ROS 
[189]) and cells were then incubated for 20 minutes at 37° C. After 20 min cells were 
analyzed with Accuri C6 flow cytometer (BD Biosciences) in FL2 channel for the 
measurement of reactive oxygen species generation.  
 
 
Immunoblotting  
 
Caski and SiHa (1X106) cells were plated per 100 mm dish and allowed to attach 
overnight. Next day cells were treated with different micromolar concentrations of 
ormeloxifene for 24 hours. After treatment, both adherent and floating cells were 
collected in 2x SDS lysis buffer (Santa Cruz Biotechnologies, Santa Cruz, CA), sonicated 
and the protein concentration was normalized using SYPRO- Orange (Molecular Probes). 
SDS – PAGE electrophoresis was done using 10% gradient gel and resolved proteins 
were transferred onto PVDF (BioRad, Hercules, CA) membrane. HPV 16 E6/E7 
(Abcam), PI3K, Akt, pAkt, Rb, PTPN13, Cyclin E and Cdk2 (Cell Signaling) and p53 
(Santa Cruz) primary antibodies were used. The primary antibodies were detected by an 
HRP-secondary antibody (anti-mouse or anti-rabbit) followed by incubation with the 
Lumi-Light detection reagent (Roche, Nutley, NJ). Band intensity was normalized with 
the β-actin loading control and the expression level was compared to the vehicle control 
(ETOH). 
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Statistical Methods 
 
Statistical analysis was determined by using an unpaired, two tailed student’s t-
test. The results were considered significant if P< 0.05. All graphs were generated using 
GraphPad Prism5 software and ModFit (for cell cycle) software.  
 
 
Results 
 
 
Ormeloxifene Alters the Morphology of Cervical Cancer Cells 
 
Phase contrast microscopic examination of cellular morphology suggested that 
after indicated time period ormeloxifene promotes clear signs of apoptosis and alters the 
morphology of treated cells. Cells started becoming round and detaching from the cell 
culture plate surface; membrane blebbing and shrinkage of cytoplasm could also clearly 
be seen in representative images of ormeloxifene treated cell (Figure 4-1 and Figure 
4-2). These obvious signs are indicative of apoptotic morphological changes. On contrast, 
the vehicle control ETOH treated cells did not have these changes in morphology. 
Control group cells were in proper shape and size and attached to the surface of plate. 
 
 
Ormeloxifene Induces Mitochondrial Membrane Potential 
 
Decreased mitochondrial membrane potential (MMP) is a clear sign of induction 
of apoptosis through the mitochondrial intrinsic pathway [190]. TMRE stains healthy and 
active mitochondria; thus, it is an indicative of live cells. The visual inspection of TMRE 
stain in Caski and SiHa cells after 24 hours of ormeloxifene treatment revealed that cells 
started losing the intensity of TMRE stain with the increasing concentration of 
ormeloxifene (Figure 4-3 and Figure 4-4). We also performed flow cytometry to 
measure the quantitative depolarization of mitochondrial membrane in Caski and SiHa 
cells and results were consistent. Ormeloxifene significantly decreased mitochondrial 
membrane potential of both cells in dose dependent manner when compared to its vehicle 
control ETOH (Figure 4-5 and Figure 4-6). 
 
 
Ormeloxifene Induces Generation of Reactive Oxygen Species 
 
Under stress conditions whether its drug treatment or radiation, tumor cells are 
known to generate of reactive oxygen species (ROS) due to the oxidative stress. 
Production of reactive oxygen species is one of the key phenomena which leads to 
apoptosis. We used DCFH-DA stain to detect the amount of reactive oxygen species 
generation after ormeloxifene treatment in Caski and SiHa cells. DCFH-DA 
(dichlorodihydrofluorescein diacetate) is a very well-known stain that is used to detect 
intracellular production of H2O2. After 24 hours of ormeloxifene treatment at 25 µM  
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Figure 4-1. Ormeloxifene altered morphology of Caski cells. 
Cells were observed and imaged under a phase contrast microscope at 200X after 24 hrs of 
ormeloxifene treatment. Cells showed clear signs of apoptosis including blebbing and 
shrinkage. 
 
 
 
 
 
Figure 4-2.  Ormeloxifene altered morphology of SiHa cells. 
Cells were observed and imaged under a phase contrast microscope at 200X after 24 hrs 
of ormeloxifene treatment. Cells showed clear signs of apoptosis including blebbing and 
shrinkage 
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Figure 4-3.  Ormeloxifene decreased mitochondrial membrane potential of Caski 
cells. 
Cells were exposed to ormeloxifene treatment for 24 hrs and afterwards stained with 
TMRE and imaged with a fluorescent microscope at 200X. Cells showed a reduction in 
TMRE fluorescence. 
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Figure 4-4. Ormeloxifene decreased mitochondrial membrane potential of SiHa 
cells. 
Cells were exposed to ormeloxifene treatment for 24 hrs and afterwards stained with 
TMRE and imaged with a fluorescent microscope at 200X. Cells showed a reduction in 
TMRE fluorescence. 
 
  
  
35 
 
 
Figure 4-5. Ormeloxifene decreased mitochondrial membrane potential (MMP) of 
Caski cells. 
Cells were treated with ormeloxifene for 24 hrs and stain with TMRE dye to detect the 
healthy mitochondria. Results were compared to vehicle control ETOH. Error bars show 
SEM, n=3. *p<0.05. 
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Figure 4-6. Ormeloxifene decreased mitochondrial membrane potential (MMP) of 
SiHa cells. 
Cells were treated with ormeloxifene for 24 hrs and stained with TMRE dye to detect the 
healthy mitochondria. Results were compared to vehicle control ETOH. Error bars show 
SEM, n=3. *p<0.05. 
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concentration, both cell lines showed elevated levels of H2O2 generation when compared 
to vehicle control ETOH as confirmed by higher intensity levels of DCFH-DA stain 
(Figure 4-7 and Figure 4-8). 
 
 
Ormeloxifene Induces Apoptosis in Cervical Cancer Cells 
 
We confirmed the ormeloxifene’s ability to induce the apoptosis by probing the 
cells with Annexin V and 7AAD stain. As Annexin V denotes the early apoptosis and 
7AAD marks the dead cells. Flow cytometer results illustrated that both Caski and SiHa 
cells after 24 hours of ormeloxifene treatment at 20 and 25 µM concentration showed a 
marked increase in the percentage of Annexin V positive cell population (Figure 4-9, 
Figure 4-10, Figure 4-11 and Figure 4-12), confirming the early apoptosis phase. We 
also observed greater percentage of AnnexinV-7AAD (double stain) positive cells in 
higher concentration (25 µM ormeloxifene) treated Caski cells (Figure 4-9) when 
compared to its vehicle control ETOH, but in a dose dependent manner in SiHa cells 
(Figure 4-10), confirming the late apoptosis phase. 
 
 
Ormeloxifene Arrest Cell Cycle in G1-S Transition by Regulating the Expression 
Level of Transition Related Proteins 
 
We further validated ormeloxifene’s ability to induce apoptosis by performing the 
cell cycle arrest assay to determine the cell population at different phases of cell cycle. 
Caski and SiHa cells were treated with 10 and 20 µM of ormeloxifene for 24 hours and 
stained with Propidium Iodide. Cells showed a blockage of progression at G1-S transition 
(Figure 4-13 and Figure 4-14). Furthermore, we confirmed the cell cycle arrest at G1-S 
transition by probing for the two transition related molecules Cyclin E and its dependent 
kinase; cyclin dependent kinase 2 (Cdk2) utilizing immunoblotting. Ormeloxifene 
significantly decreased the expression of both the proteins at 20 µM concentration when 
compared to the vehicle control ETOH (Figure 4-15 for immunoblots; Figure 4-16 and 
Figure 4-17 for density quantification). 
 
 
Ormeloxifene Downregulates PI3K-Akt Pathway 
 
PI3K-Akt cell survival oncogenic pathway is overly expressed in cervical cancer 
cells. The pathway is required for cell cycle progression from G1 phase to S phase. 
Inhibition of PI3K-Akt pathway is an important tool for developing the treatment 
strategies for cervical cancer. We utilized immunoblotting assay to evaluate the inhibitory 
effects of ormeloxifene on PI3K-Akt pathway. Ormeloxifene decreased the total Akt 
expression slightly but phosphorylated and active form of Akt (pAkt) and PI3K were 
decreased markedly (Figure 4-18). Figure 4-19, Figure 4-20 and Figure 4-21 indicate 
the densitometric analysis of band intensity of immunoblots showed in Figure 4-18. 
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Figure 4-7. Ormeloxifene enhanced the generation of reactive oxygen species 
(ROS) in Caski cells. 
Cels were treated with ormeloxifene for 24 hrs and stain with DCFH-DA dye to detect 
H2O2 formation. Results were compared to vehicle control ETOH. Error bar shows SEM, 
n=3. *p<0.05. 
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Figure 4-8. Ormeloxifene enhanced the generation of reactive oxygen species 
(ROS) in SiHa cells. 
Cells were treated with ormeloxifene for 24 hrs and stain with DCFH-DA dye to detect 
H2O2 formation. Results were compared to vehicle control ETOH. Error bar shows SEM, 
n=3. *p<0.05. 
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Figure 4-9. Cell population diagram of Caski cells obtained with Flow Cytometer 
representing percentage of cells stained with either Annexin V or 7AAD or both or 
none. 
 
 
 
 
 
Figure 4-10. Cell population diagram of SiHa cells obtained with Flow Cytometer 
representing percentage of cells stained with either Annexin V or 7AAD or both or 
none.  
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Figure 4-11.Ormeloxifene induced apoptosis of Caski cells. 
Cells were treated with ormeloxifene for 24 hours and analyzed by flow cytometry using 
Annexin V and 7AAD dyes. Results were compared to vehicle control ETOH. Error bars 
show SEM, n=3. *p<0.05. 
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Figure 4-12. Ormeloxifene induced apoptosis of SiHa cells. 
Cells were treated with ormeloxifene for 24 hours and analyzed by flow cytometry using 
Annexin V and 7AAD dyes. Results were compared to vehicle control ETOH.  Error bars 
show SEM, n=3. *p<0.05.  
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Figure 4-13. Ormeloxifene arrested cell cycle at G1-S transition in Caski Cells. 
Cell cycle population diagram of Caski cells obtained with ModFit software representing 
percentage of different cell population stained with propidium iodide.  
 
 
 
 
 
Figure 4-14. Ormeloxifene arrested cell cycle at G1-S transition in SiHa cells. 
Cell cycle population diagram of SiHa cells obtained with ModFit software representing 
percentage of different cell population stained with propidium iodide.  
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Figure 4-15. Ormeloxifene downregulated the expression levels of Cyclin E and 
Cdk2 in Caski cells. 
Cells were treated with ormeloxifene for 24 hrs and immunoblots were preformed to 
detect Cyclin E and Cdk2 proteins. β-actin was used as a loading control. 
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Figure 4-16. Densitometric quantitation of band intensity of Cyclin E.  
Band intensity was normalized to β-actin and scaled to the ETOH control. Bars = Relative 
Expression Level, Error bars show SEM, n=3. *p<0.05. 
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Figure 4-17. Densitometric quantitation of band intensity of Cdk2. 
Band intensity was normalized to β-actin and scaled to the ETOH control. Bars = Relative 
Expression Level, Error bars show SEM, n=3. *p<0.05. 
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Figure 4-18. Ormeloxifene downregulated the expression levels of PI3K/Akt 
pathway in Caski cells. 
Cells were treated with ormeloxifene for 24 hrs and immunoblots were preformed to 
detect PI3K, Akt and pAkt proteins. β-actin was used as a loading control. 
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Figure 4-19. Densitometric quantitation of band intensity of PI3K. 
Band intensity was normalized to β-actin and scaled to the ETOH control. Bars = 
Relative Expression Level, Error bars show SEM, n=3. *p<0.05. 
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Figure 4-20. Densitometric quantitation of band intensity of pAkt. 
Band intensity was normalized to β-actin and scaled to the ETOH control. Bars = 
Relative Expression Level, Error bars show SEM, n=3. *p<0.05. 
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Figure 4-21. Densitometric quantitation of band intensity of Akt. 
Band intensity was normalized to β-actin and scaled to the ETOH control. Bars = 
Relative Expression Level, Error bars show SEM, n=3. *p<0.05. 
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CHAPTER 5.    ANALYSIS OF ORMELOXIFENE’S EFFECT ON HPV 
REGULATION ONCOGENESIS IN CERVICAL CANCER 
 
 
Materials and Methods  
 
 
Quantitative PCR   
 
1X106 Caski cells were plated per 100 mm dish and allowed to attach overnight. 
After 24 hours cells were treated with ormeloxifene at 2 different micromolar 
concentrations (10 µM and 20 µM) for 6 hours. After indicated time, adherent cells were 
collected and RNA was extracted with the Qiagen RNeasy kit (Qiagen Inc., Valencia, 
CA). Reverse transcription was performed with the High Capacity RNA to cDNA kit and 
amplified with SYBR Green PCR master mix (both from Applied Biosystems).  The 
cDNA was amplified with primers specific for HPV16 E6, HPV16 E7 and β2-
microglobulin. E6-F: caaaccgttgtgtgatttgttaatta; E6-R: gctttttgtccagatgtctttgc; E7-F: 
ccggacacagcccattacaa; E7-R: cgaatgtctacgtgtgtgctttg; β2M-F: tgagtatgcctgccgtgtga; 
β2M-R: tgatgctgcttacatgtctcgat [130]. Each reaction was performed in duplicate with a 
MyiQ single color real time PCR thermo cycler and analyzed with Genex (Microsoft 
Excel macro provided by BioRad).  The results were first normalized to the endogenous 
control (β2-microglobulin) and then the expression level was scaled to the vehicle control 
(ETOH).  
 
 
Immunoblotting  
 
Caski and SiHa (1X106) cells were plated per 100 mm dish and allowed to attach 
overnight. Next day cells were treated with different micro molar concentrations of 
ormeloxifene for 24 hours. After treatment, both adherent and floating cells were 
collected in 2x SDS lysis buffer (Santa Cruz Biotechnologies, Santa Cruz, CA), sonicated 
and the protein concentration was normalized using SYPRO- Orange (Molecular Probes). 
SDS – PAGE electrophoresis was done using 10% gradient gel and resolved proteins 
were transferred onto PVDF (BioRad, Hercules, CA) membrane. HPV 16 E6/E7 
(Abcam), PI3K, Akt, pAkt, Rb, PTPN13, Cyclin E and Cdk2 (Cell Signaling) and p53 
(Santa Cruz) primary antibodies were used. The primary antibodies were detected by an 
HRP-secondary antibody (anti-mouse or anti-rabbit) followed by incubation with the 
Lumi-Light detection reagent (Roche, Nutley, NJ). Band intensity was normalized with 
the β -actin loading control and the expression level was compared to the vehicle control 
(ETOH). 
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Statistical Methods 
 
Statistical analysis was determined by using an unpaired, two tailed student’s t-test. 
The results were considered significant if P< 0.05. All graphs were generated using 
GraphPad Prism5 software.  
 
 
Results 
 
 
Ormeloxifene Decreases the Expression of HPV Oncogenes E6 and E7 
 
Oncogenes E6 and E7 are responsible for continuous cell division which results in 
development of cervical cancer. Expression of human papillomavirus E6 and E7 is a very 
important consideration for cervical cancer treatment. Quantitative RT – PCR was 
performed to determine the expression of HPV oncogenes E6 and E7 in Caski cells. 
Ormeloxifene significantly inhibits the expression of E6 and E7 after 6 hours of 
Ormeloxifene treatment (10 µM and 20 µM doses) (Figure 5-1 and Figure 5-2). The 
indicated treatment was compared with vehicle control ETOH. We also assessed the 
downregulation of oncogenic signaling at the translational level by performing 
immunoblotting. Both oncoproteins showed a marked reduction in the expression level 
compared to the vehicle control ETOH (Figure 5-3). Figure 5-4 and Figure 5-5 indicate 
the densitometric analysis of band intensity of Figure 5-3. 
 
 
Ormeloxifene Restores the Tumor Suppressor Signaling 
 
The oncogenic properties of HPV E6 and E7 are increased when E6 and E7 bind 
to the suppressor proteins p53, Rb and PTPN13. Ormeloxifene’s effect on these tumor 
suppressing molecules was determined by the immunoblotting assays. We treated Caski 
cervical cancer cells with 10 and 20 µM concentration of ormeloxifene for 24 hours and 
probed for three tumor suppressor proteins. We observed a slight but noticeable decrease 
in the expression of wild type p53, but Rb and PTPN13 proteins also showed a marked 
decrease in the expression after ormeloxifene treatment at 20 µM dose (Figure 5-6). 
Figure 5-7, Figure 5-8 and Figure 5-9 indicate the densitometric analysis of band 
intensity of Figure 5-6.  
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Figure 5-1. Ormeloxifene decreased HPV E6 mRNA. 
Caski cells were treated with ormeloxifene for 6 hrs and mRNA level of HPV E6 was 
determined by quantitative PCR. Expression levels were normalized to a house keeping 
gene (β-2-Microgloblin) and scaled to the vehicle control (ETOH).  Bars = Relative 
Expression Level, Error bars show SEM, n=3. *p<0.05. 
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Figure 5-2. Ormeloxifene decreased HPV E7 mRNA. 
Caski cells were treated with ormeloxifene for 6 hrs and mRNA level of HPV E7 was 
determined by quantitative PCR. Expression levels were normalized to a house keeping 
gene (β-2-Microgloblin) and scaled to the vehicle control (ETOH).  Bars = Relative 
Expression Level, Error bars show SEM, n=3. *p<0.05. 
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Figure 5-3. Ormeloxifene inhibited HPV E6 and E7 proteins. 
Caski cells were treated with ormeloxifene for 24 hrs and immunoblots were preformed 
to detect HPV E6 and E7 proteins. β-actin was used as a loading control. 
 
  
  
56 
 
 
Figure 5-4. Densitometric quantitation of band intensity of HPV E6. 
Band intensity was normalized to β-actin and scaled to the ETOH control. Bars = 
Relative Expression Level, Error bars show SEM, n=3. *p<0.05. 
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Figure 5-5. Densitometric quantitation of band intensity of HPV E7. 
Band intensity was normalized to β-actin and scaled to the ETOH control. Bars = 
Relative Expression Level, Error bars show SEM, n=3. *p<0.05. 
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Figure 5-6. Ormeloxifene restored the expression levels of p53, Rb and PTPN13 
tumor suppressor proteins. 
Caski cells were treated with ormeloxifene for 24 hrs and immunoblots were preformed 
to detect p53, Rb and PTPN13 proteins. β-actin was used as a loading control. 
 
  
  
59 
 
 
Figure 5-7. Densitometric quantitation of band intensity of p53. 
Band intensity was normalized to β-actin and scaled to the ETOH control. Bars = 
Relative Expression Level, Error bars show SEM, n=3. *p<0.05. 
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Figure 5-8. Densitometric quantitation of band intensity of Rb. 
Band intensity was normalized to β-actin and scaled to the ETOH control. Bars = 
Relative Expression Level, Error bars show SEM, n=3. *p<0.05. 
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Figure 5-9. Densitometric quantitation of band intensity of PTPN13. 
Band intensity was normalized to β-actin and scaled to the ETOH control. Bars = 
Relative Expression Level, Error bars show SEM, n=3. *p<0.05. 
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CHAPTER 6.    IN VITRO EXAMINATION OF ORMELOXIFENE WITH 
RADIATION AS A COMBINATION THERAPY 
 
 
Materials and Methods  
 
 
Cell Proliferation Assays 
 
In order to analyze the combinatorial effects of ormeloxifene with radiation we 
utilized Caski cells. Cells were seeded at 200,000 cells in 2 mL media per well of 6-well 
plates and allowed to adhere overnight. Next day the treatment was performed in two 
different conditions. The first set of cells was pre-treated with 10 µM ormeloxifene for 24 
hours and then next morning exposed to 4 Gy dose of radiation for another 24 hours.  The 
second set of cells was co-treated with 10 µM ormeloxifene and 4 Gy dose of radiation at 
the same time for next 24 hours. A Biological X-ray irradiator (Radiation Source, 
Alpharetta, GA) was used to irradiate the cells. After the indicated time cells were 
trypsized, washed with PBS and counted with coulter counter (Beckman coulter counter, 
Life Sciences). Experiment was done in triplicate. 
 
 
Colony Forming Assays  
 
Caski cervical cancer cells were seeded at 200 cells in 2 mL/well in 6 well plates 
and allowed to attach overnight. Following day, cells were pretreated with different 
concentrations of ormeloxifene (2, 4, 6 and 8 µM) for 6 hours. After 6 hours, cells were 
exposed to radiation at 4 Gy dose. Cells were then maintained for next 12-14 days. On 
the day of termination, cells were washed, fixed in cold methanol and stained with 
hematoxylin (Thermo Fisher). Visible colonies (~50 cells) were counted manually. Each 
experiment was done in triplicates and repeated 3 individual times. 
 
 
Statistical Methods 
 
Statistical analysis was determined by using an unpaired, two tailed student’s t-
test. The results were considered significant if P< 0.05. All graphs were generated using 
GraphPad Prism5 software.  
 
 
Results 
 
Ormeloxifene treatment induced radio-sensitization in Caski cervical cancer cells. 
We performed short term and long term studies to analyze ormeloxifene’s effect in radio-
sensitization in Caski cells. We observed that after 24 hours of radiation, number of live 
cells significantly decreased with both pretreatment (Figure 6-1 and Figure 6-2) and co-
treatment (Figure 6-3 and Figure 6-4) of ormeloxifene when compared with radiation   
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Figure 6-1. Caski cells were pretreated with ormeloxifene and exposed to 
radiation.  
Combination treatment of ormeloxifene and radiation showed an inhibitory effect on 
cellular growth/ proliferation. Images were taken at 100X. 
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Figure 6-2. Caski cells were pretreated with ormeloxifene and exposed to 
radiation and cells were counted with Coulter counter. 
Results were normalized to the ETOH control (for ormeloxifene) and to radiation and 
free ORM (for combination). Error bars show SEM, n=3. *p<0.05. Combination 
treatment of ormeloxifene and radiation showed an inhibitory effect on cellular growth/ 
proliferation. 
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Figure 6-3. Caski cells were treated with ormeloxifene and exposed to radiation 
simultaneously. 
Combination treatment of ormeloxifene and radiation showed an inhibitory effect on 
cellular growth/ proliferation. Images were taken at 100X. 
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Figure 6-4. Caski Cells were treated with ormeloxifene and exposed to radiation 
simultaneously and cells were counted with Coulter counter. 
Results were normalized to the ETOH control (for ormeloxifene) and to; radiation and 
free ORM (for combination). Error bars show SEM, n=3. *p<0.05. Combination 
treatment of ormeloxifene and radiation showed an inhibitory effect on cellular growth/ 
proliferation. 
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alone and ormeloxifene alone treatment groups. However, the co-treatment showed more 
inhibition of cellular growth than pretreatment. The results were consistent with long 
term pretreatment of ormeloxifene and significantly sensitized Caski cells to radiation as 
confirmed by decreased number of colonies when compared to radiation alone and 
ormeloxifene alone treated groups (Figure 6-5). The quantification of colonies is 
presented in Figure 6-6.  
 
 
 
 
 
 
Figure 6-5. Combination treatment of ormeloxifene and radiation reduced the 
clonogenic potential of Caski cells. 
Cells were pretreated with ormeloxifene and exposed to radiation. Cells were observed 
under phase contrast microscope and images were taken at 200X. 
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Figure 6-6. Bar graph showing that combination treatment of ormeloxifene and 
radiation reduced the clonogenic potential of Caski cells. 
Cells were pretreated with ormeloxifene and exposed to radiation. Results were 
normalized to the ETOH control (for ormeloxifene) and to radiation and free ORM (for 
combination). Error bars show SEM, n=3. *p<0.05. 
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CHAPTER 7.    DEVELOPMENT AND PHYSICOCHEMICAL 
CHARACTERIZATION OF ORMELOXIFENE LOADED PLGA 
NANOPARTICLES* 
 
 
Materials and Methods 
 
 
Synthesis of PLGA-ORM NPs 
 
PLGA-ORM NPs were prepared by following a nano-precipitation technique 
[176, 177] with a modified protocol (Figure 7-1). The stable PLGA-ORM NP suspension 
was obtained using polymer stabilizers, poly(vinyl alcohol) (PVA) and poly(L-lysine) 
(PLL). Briefly, to 20 mL aqueous 1% PVA solution, 90 mg of PLGA and 20 mg ORM 
were dissolved in 8-10 mL acetone that was added drop-wise using a 1 mL pipette over 
10 min under a constant stirring on a magnetic stir plate at 500 rpm. This process leads to 
a milky-white suspension. This suspension was left overnight at room temperature in the 
chemical fume hood under stirring condition, allowing for complete evaporation of the 
acetone. Then, to this suspension, 10 mg PLL in 5 mL water was added and stirred at 500 
rpm for 6 hr. The resulted PLGA-ORM NPs in suspension were purified and recovered 
by ultracentrifugation at 20,000 rpm for 2 hr at 4º C, three times, using a Rotor 30.50 on 
an Avanti J-30I Centrifuge (Beckman Coulter, Fullerton, CA), followed by re-suspension 
in ultra-purified water and sonication on ice for 1 min (using a probe sonicator). Then the 
supernatant containing PLGA-ORM NPs was transferred to a sterile cryo-vial, frozen at -
80º C for 2 hr, and immediately lyophilized for 2-3 days using the Labconco Freeze Dry 
System (−48º C, 133 × 10−3 mBar; Labconco, Kansas City, MO). The lyophilized vials 
were stored in a 4º C cold room for further in vitro and in vivo use. This formulation was 
named PLGA-ORM 20. Similarly, PLGA-ORM formulations with 5, 10, 15, and 25 mg 
ORM were prepared and termed as PLGA-ORM 5, PLGA-ORM 10, PLGA-ORM 15, 
and PLGA-ORM 25, respectively. Additionally, parent PLGA NPs were also prepared 
without ORM that served as a control for all in vitro and in vivo experiments. 
 
 
PLGA-ORM NPs Characterization 
 
Particle Size 
 
PLGA-ORM NPs were characterized for the surface morphology and size of 
particles using a JEOL-1210 transmission electron microscope (TEM) (JEOL Ltd., 
Tokyo, Japan) operating at 60 kV.  For this, 50 µL suspension of 1 mg/mL PLGA-ORM 
NPs was carefully dispersed on 200 mesh formvar-coated copper TEM-grid  (grid size: 
 
 
----------------------------- 
* Adapted with permission. Khan, S., et al., Nanoparticle formulation of ormeloxifene for 
pancreatic cancer. Biomaterials, 2015. 53: p. 731-743.  
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Figure 7-1. Diagram showing preparation method (nano-precipitation) of PLGA-
ORM nanoformulation.  
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97 μm) (Ted Pella, Inc., Redding, CA), followed by staining with 2% w/v of uranyl 
acetate solution. The excess solution on the grid was removed by air drying. Then, 
particles on the TEM-grid were imaged under TEM. We also used a dynamic light 
scattering system to confirm particle size. 
 
Drug Loading 
 
To determine ORM loading, freshly prepared PLGA-ORM NPs were centrifuged 
three times at 20,000 rpm for 2 hr at 4º C using Avanti J-30I Centrifuge, followed by re-
suspension in ultra-purified water and sonication on ice for 1 min. The supernatant was 
removed, the pellet was re-suspended, lyophilized, and ORM from pellet was extracted 
for 2 days with 1 mL of acetonitrile. The concentration of ORM in the extract was 
analyzed using an UltiMate high-performance liquid chromatography (HPLC) (Dionex 
Corporation) equipped with UltiMate 3000 injector, RS variable wavelength detector, and 
an Acclaim polar advantage column of 3 μm 120 Å (4.6 × 150 mm). The mobile-phase 
consisted of a mixture of 1% citric acid:acetonitrile (40:60, v/v). 50 µL of the extracted 
samples were injected using an auto injector (Model 508, Beckmann Instruments) and 
peaks were analyzed using a UV detector at 279 nm. The retention time was observed at 
~18-20 min [191]. A linear calibration curve in the range of 1 to 10 µg/mL was obtained 
at the same working condition for ORM. From this data, the ORM loading content was 
calculated as follows: 
 
Fourier Transform Infra-Red 
 
FT-IR spectra of PLGA-ORM NPs were obtained using a Fourier Transform 
infra-red (FT-IR) microscope (Smiths Detection, Danbury, CT). The spectra data, 4,000–
750 cm-1, was acquired at a scanning speed of cm-1 for 32 scans by placing lyophilized 
PLGA-ORM NPs powder on the attenuated total reflection objective. The final data is 
reported as an average data of 32 scans.  
 
Thermal Analysis 
 
Thermal analysis of PLGA-ORM NPs was carried out using differential scanning 
calorimetry (DSC) and thermo-gravimetric analyzer (TGA) to investigate the physical 
status and thermal profile. Both DSC and TGA profiles were accomplished on a Q50 
TGA (TA Instruments, New Castle, DE) under dry nitrogen atmosphere (a flow rate of 
10 mL/min) from 25° C to 700° C at the heating rate of 10° C/min. 
 
In Vitro Drug Release (Dialysis Bag Method) 
 
Dialysis membrane bag based drug release method [1] (Figure 7-2) was 
employed to evaluate release of ormeloxifene (ORM) from PLGA-ORM 20 
nanoformulation in PBS containing 0.1% (wt/vol) Tween-80 (PBS-T). In detail, 1 mL of 
180 µg ORM/mL PLGA-ORM 20 suspension was placed in a dialysis membrane bag 
(molecular weight cut off size, 12 kDa, Sigma–Aldrich Co., St. Louis, MO) which was  
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Figure 7-2. Representation of in vitro drug release in house system. 
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immersed in 3 mL PBS-T, pH 7.4 in a tube at 37° C and rotated at 100 rpm on an orbital 
shaker. The released drug from PLGA-ORM 20 into PBS-T was estimated at indicated 
time points [1 hr, 3 hrs, 6 hrs, day 1 (24 hrs), day 3 (72 hrs), day 5 (120 hrs), and day 7 
(168 hrs)] using acetonitrile for drug extraction. The released ORM was analyzed by 
Waters HPLC Alliance system equipped with an e2695 separations module and a Waters 
2998 photo-diode array (PDA) detector (Milford, MA, USA). Samples were analyzed 
using a Waters HPLC system which has an auto injector and the instrument was operated 
by use of Empower2® software (Milford, MA, USA). Components were separated on a 
Waters C18 reversed- phase column (Milford, MA, USA) with 300 mm × 4.6 mm 
dimensions and 5 μm particle size. A linear calibration curve in the range of 0.1 to 10 
µg/mL was obtained as identical to drug release process and calculated the released drug 
from PLGA-ORM formulation. The data is represented as percent release. 
 
Colloidal Stability of Nanoparticles in Whole Human Serum Albumin 
(WHSA) 
 
Before testing nanoparticles in vivo, it is important to confirm in vitro stability of 
nanoparticles with human serum. If nanoparticles are not compatible with serum, they 
aggregate and result in higher absorbance value. To study human serum compatibility of 
our formulation, we utilized Spectrophotometer absorption method as due to the turbidity 
of the serum, dynamic light scattering method is not very useful for authentication. For 
this experiment, PLGA-ORM was finally prepared at 1 mg/mL concentration; from this 
stock solution we incubated 100 µL of this novel formulation with 100 µL of whole 
human serum albumin at 37º C for different time points from 0 hr to 48 hrs. At each time 
point, absorbance was measured at 560 nm utilizing Cytation 3 imaging multi microplate 
reader (BioTek). 
 
 
Statistical Methods 
 
Statistical analysis was determined by using an unpaired, two tailed student’s t-
test. The results were considered significant if P< 0.05. All graphs were generated using 
GraphPad Prism5 software and Statistical Package for the Social Sciences, version 11.5 
(SPSS Inc., Chicago, IL). 
 
 
Results 
 
The primary objectives of this study were to improve the anti-cancer activity of 
ORM, using a nanoparticle formulation (Figure 7-3) [192], and to examine its efficacy in 
human cervical cancer cell line and xenograft mouse models. The motive to make an 
ORM nanoformulation is that; nanoparticles (NPs) are known to preferentially reach and 
accumulate in tumor tissue(s) due to leaky vasculature by the Enhanced Permeation and 
Retention (EPR) effect [193, 194]. For such phenomenon, a better example is Abraxane®, 
which has been widely used in the clinic for the treatment of various types of cancers,  
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Figure 7-3. Schematic of PLGA-ORM NP formulations.  
Reprinted with permission. Khan, S., et al., Nanoparticle formulation of ormeloxifene for 
pancreatic cancer. Biomaterials, 2015. 53: p. 731-743.  
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including pancreatic cancer. This confirms that the nanodrug formulation(s) may have 
superior outcome over traditional chemotherapy in clinical oncology. Therefore, we have 
generated a PLGA-based ORM nanoparticle formulation, PLGA-ORM NPs. The 
selection of the PLGA NP-based formulation to deliver ORM is due to the fact that the 
PLGA co-polymer has shown promising results in in vitro, in vivo, pre-clinical, and 
human studies (for example, BIND-014, a docetaxel PLGA NP formulation). Based on 
these facts, we have engineered an optimized PLGA-ORM NP formulation, composed of 
a PLGA core that is subsequently coated with poly(vinyl alcohol) (PVA) and poly(l-
lysine) (PLL) for efficient delivery and targeting of ORM to cancer cells. This 
formulation (Figure 7-3), has several unique properties: (a) the PLGA core is capable of 
loading and releasing ORM in sustained manner, more importantly, it was approved by 
US Food and Drug Administration, (b) PVA, a widely used stabilizer for most of the 
polymer NP formulation(s), supports stability of formulation over 6 month(s) and avoids 
non-specific adsorption of human serum proteins in in vivo condition, (c) PLL promotes 
cellular internalization and is less toxic compared to other polycationic polymers, and (d) 
amine functional groups on NPs (PLL) are useful for antibody conjugation through a 
PEG-linker, notably, the N-Hydroxysuccinimide (NHS) group for targeting tumor/cancer 
cells.  
 
 
Characterization of PLGA-ORM NPs 
 
PLGA and PLGA-ORM NP formulations (PLGA-ORM 5, PLGA-ORM 10, 
PLGA-ORM 15, PLGA-ORM 20, and PLGA-ORM 25) were successfully prepared by 
increasing amounts of ORM in the composition (0 to 25 mg). Drug loading was assessed 
by HPLC method that indicated all the nanoformulations resulted in ORM encapsulation 
(> 80-90% encapsulation efficiency). Based upon loading analysis, we selected PLGA-
ORM 20 formulation for all our further cellular work. All formulations exhibit 
homogeneous spherical shapes and smooth surfaces without cracks (Figure 7-4, Figure 
7-5, Figure 7-6, Figure 7-7, Figure 7-8 and Figure 7-9) [192]. The mean particle size of 
PLGA or PLGA-ORM NPs was found to be 30.8 ± 1.5 nm (PLGA NPs), 68.4 ± 1.5 nm 
(PLGA-ORM 5), 70.8 ± 4.5 nm (PLGA-ORM 10), 87.3 ± 1.5 nm (PLGA-ORM 15), 
101.4 ± 1.5 nm (PLGA-ORM 20), and 175.2 ± 1.5 nm (PLGA-ORM 25). The size of 
PLGA-ORM NP formulations was mostly between 50 nm to 250 nm and was narrowly 
distributed in each formulation. (Figure 7-10) [192]. We also measured particle size 
using DLS method; data illustrated a particle size under 280 nm for all formulations 
(Figure 7-11). It was noticed that the formulation particle size increased when drug 
loading used for the particle preparation increased. However, all these formulations were 
small enough in size and suitable for tumor specific accumulation via the EPR effect 
[195]. To confirm the ORM existence in PLGA-ORM NP formulations, FT-IR (Figure 
7-12), DSC (Figure 7-13), and TGA (Figure 7-14) studies were conducted  [192]. In the 
FT-IR spectrum of PLGA NPs (Figure 7-12, navy blue line), the intense peaks were 
found at 1741 cm-1, 1181 cm-1, and 1010 cm-1 due to C=O stretching of ester, C-O 
stretching of ester, and glycosidic (C–O–C/C–C/C–O) stretch vibrations. Because ORM 
has similar major functional groups in its structures (Figure 7-12, black line), after  
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Figure 7-4. Representative TEM images of PLGA alone nanoparticles and Scale 
bars on TEM images equal 200 nm.  
Reprinted with permission. Khan, S., et al., Nanoparticle formulation of ormeloxifene for 
pancreatic cancer. Biomaterials, 2015. 53: p. 731-743. 
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Figure 7-5. Representative TEM images of PLGA-ORM 5 nanoparticles and 
Scale bars on TEM images equal 200 nm.  
Reprinted with permission. Khan, S., et al., Nanoparticle formulation of ormeloxifene for 
pancreatic cancer. Biomaterials, 2015. 53: p. 731-743. 
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Figure 7-6. Representative TEM images of PLGA-ORM 10 nanoparticles and 
Scale bars on TEM images equal 200 nm. 
Reprinted with permission. Khan, S., et al., Nanoparticle formulation of ormeloxifene for 
pancreatic cancer. Biomaterials, 2015. 53: p. 731-743. 
 
 
 
  
  
79 
 
 
Figure 7-7. Representative TEM images of PLGA-ORM 15 nanoparticles and 
Scale bars on TEM images equal 200 nm.  
Reprinted with permission. Khan, S., et al., Nanoparticle formulation of ormeloxifene for 
pancreatic cancer. Biomaterials, 2015. 53: p. 731-743. 
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Figure 7-8. Representative TEM images of PLGA-ORM 20 nanoparticles and 
Scale bars on TEM images equal 200 nm.  
Reprinted with permission. Khan, S., et al., Nanoparticle formulation of ormeloxifene for 
pancreatic cancer. Biomaterials, 2015. 53: p. 731-743. 
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Figure 7-9. Representative TEM images of PLGA-ORM 25 nanoparticles and 
Scale bars on TEM images equal 200 nm. 
Reprinted with permission. Khan, S., et al., Nanoparticle formulation of ormeloxifene for 
pancreatic cancer. Biomaterials, 2015. 53: p. 731-743. 
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Figure 7-10. Evaluation of nanoparticle size from TEM images using ImageJ 
software, data represents an average of at least 20 particles in two different fields of 
view in TEM images. 
Reprinted with permission. Khan, S., et al., Nanoparticle formulation of ormeloxifene for 
pancreatic cancer. Biomaterials, 2015. 53: p. 731-743. 
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Figure 7-11. PLGA-ORM particle size representation using DLS system. 
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Figure 7-12. FT-IR spectra of ORM, PLGA NPs and PLGA-ORM NP 
formulations confirmed that ormeloxifene is successfully encapsulated in PLGA 
core. 
Reprinted with permission. Khan, S., et al., Nanoparticle formulation of ormeloxifene for 
pancreatic cancer. Biomaterials, 2015. 53: p. 731-743. 
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Figure 7-13. DSC endothermic curves of PLGA and PLGA-ORM NP 
nanoformulations confirmed that ormeloxifene is successfully encapsulated in 
PLGA core. 
Reprinted with permission. Khan, S., et al., Nanoparticle formulation of ormeloxifene for 
pancreatic cancer. Biomaterials, 2015. 53: p. 731-743. 
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Figure 7-14. Thermogravimetric weight loss curves of PLGA and PLGA-ORM NP 
nanoformulations suggested ORM’s successful incorporation in the PLGA-ORM 
NP formulation. 
Reprinted with permission. Khan, S., et al., Nanoparticle formulation of ormeloxifene for 
pancreatic cancer. Biomaterials, 2015. 53: p. 731-743. 
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encapsulation no additional peaks appeared in FT-IR spectra of PLGA-ORM NPs 
(Figure 7-12), red to magenta lines, upwards). On the other hand, additional peaks 
were not attained in FT-IR after ORM encapsulation due to a higher degree of miscibility 
of ORM in the PLGA polymer matrix [196]. On the other hand, ORM may have been 
masked by the bands produced by the PLGA polymer matrix. This behavior was further 
confirmed with DSC analysis (Figure 7-13). DSC curves of pure PLGA NP formulation 
exhibit an endothermic peak at ~ 79º C (Figure 7-13, black line), indicative of the glass 
transition temperature of the formulation. Due to incorporation of ORM in the PLGA-
ORM formulations, an exothermic peak appeared at ~ 58º C (Figure 7-13, red to 
magenta lines, downwards). Because of its superior blending of PLGA NPs and ORM 
in the PLGA-ORM NP formulations, PLGA glass transition peak disappeared or lowered 
the PLGA glass transition temperature. This indicates that ORM in nanoformulations is 
highly miscible. On the other hand, it appears that there is a significant reduction of 
crystallinity of the formulation. The presence of ORM in nanoformulations was further 
confirmed by TGA (Figure 7-14). The significant weight loss of PLGA NPs begins at 
250º C to 580º C (Figure 7-14, black line). This behavior is further accelerated due to 
the presence of ORM in PLGA-ORM nanoformulations (Figure 7-14, red to magenta 
lines). Approximately, 55% and 80% weight loss were observed at 350º C and 550º C for 
PLGA NP formulations while PLGA-ORM NP formulations show 74% and 95%, 
respectively. Such greater weight loss is attributed to the presence of ORM in the 
nanoformulations.  
 
In vitro Release Profile 
 
In vitro drug release profile is an important experiment for developing a 
successful nanoformulation that qualifies for its use in vivo. Free drugs are readily 
available for the system so they can have a quick effect but soon they get cleared from 
the system. On the other hand nanoformulations release at the sustained rate, thus, carry 
better therapeutic efficacy over free drugs. The release profile of ORM from PLGA-
ORM 20 is presented in (Figure 7-15) [192]. The release of ORM is relatively rapid at 1-
3 hrs and thereafter the release pattern is gradual and sustained. 
 
Serum Stability of PLGA-ORM 
 
Nanoparticles can easily aggregate or disintegrate or leak drug upon their 
administration to in vivo system where particles come in contact with systemic 
blood/serum. Therefore, it becomes necessary to evaluate stability of nanoparticles with 
serum. We utilized whole human serum to assess the stability of our PLGA-ORM 
nanoformulation. Results from absorption method indicated that this formulation is 
highly stable with human serum as confirmed by no or negligible change absorbance 
(Figure 7-16). Higher absorbance value is an indicative of higher degree of aggregation. 
  
  
88 
 
 
Figure 7-15. Sustained in vitro release profile of PLGA-ORM. 
Reprinted with permission. Khan, S., et al., Nanoparticle formulation of ormeloxifene for 
pancreatic cancer. Biomaterials, 2015. 53: p. 731-743. 
 
 
 
 
 
Figure 7-16. Whole human serum stability profile of PLGA-ORM.  
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CHAPTER 8.    EVALUATION OF IN VITRO UPTAKE AND ANTI-
PROLIFERATIVE ACTIVITY OF PLGA-ORM  
 
 
Materials and Methods 
 
 
Cellular Internalization of Nano-ORM in Caski and SiHa Cervical Cancer Cells 
 
To determine the cellular uptake of nanoparticles in cervical cancer cells, we 
incorporated 5 mg coumarin-6 green fluorescent dye with our PLGA-ORM formulation. 
200,000 cells were seeded in 6-well plate and allowed to attach overnight. Next morning, 
cells were treated with coumarin-6 labeled PLGA-ORM and its vehicle control PLGA 
NPs respectively for 1 and 3 hours, washed twice with PBS and plates were imaged with 
a fluorescence microscope (Nikon Eclipse, Melville, NY). After imaging cells were 
trypsinized, washed with PBS and collected for uptake measurement by flow cytometer. 
Fluorescence levels from cells were measured with FL1 channel in Accuri C6 flow 
cytometer (BD Biosciences, CA) 
 
 
Transmission Electron Microscopy (TEM) 
 
For the uptake analysis by TEM, we plated Caski and SiHa cells at 200,000/well 
in 6 well plates and allowed to adhere overnight. Next morning, cells were treated with 
free ORM, PLGA-ORM and their vehicle controls ETOH and PLGA NPs respectively 
for 3 hours. After 3 hours, cells were trypsinized, washed with PBS, centrifuged and the 
pellet was collected. After the final pellet collection, it was fixed with 2% glutaraldehyde 
buffer, rinsed with 100 mM Na-cacodylate and further processed for TEM analysis. 
 
 
Cell Association Study 
 
Both cells were plated in 60 mm dish for the overnight attachment. Next day, cells 
were pre-incubated either at physiological temperature 37º C or at cold temperature 4º C 
for an hour before the drug treatment. After an hour, cells were exposed to coumarin-6 
(green fluorescent dye) labeled PLGA-ORM nanoparticles at 10, 20 and 25 µM 
concentrations for an additional hour. Next, cells were washed twice with PBS, trypsized, 
centrifuged, collected in PBS and analyzed with Accuri BD C6 flow cytometer in FL1 
channel. 
 
 
Cellular Uptake Mechanism 
 
For this analysis, both cell lines Caski and SiHa were seeded at 2x105/well in a 6-
well format plate and allowed to attach overnight. Next morning, cells were pretreated 
with different endocytosis pathway inhibitors such as Genistein (caveola mediated 
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endocytosis at 200 µM), Amiloride (micropinocytosis endocytosis at 10 mM), Nocodazol 
(microtubule mediated endocytosis at 20 µM), Chloropromazen (clathrin mediated 
endocytosis at 10 µg/mL) and Methyle-β-cyclodextrin (lipid rafts mediated endocytosis 
at 10 mM) for 1 hour.  Thereafter, cells were exposed to coumarin-6 (green fluorescent 
dye) labeled PLGA-ORM nanoparticles for the next hour at 37º C.  After an hour, cells 
were washed twice with PBS, trypsinized, centrifuged, collected in PBS and analyzed 
with Accuri BC C6 flow cytometer in FL1 channel.  
 
 
Cell Proliferation 
 
Both Caski and SiHa (5000 cells/well) cell lines were seeded in 96 well plates and 
allowed to attach overnight. Following day, cells were treated with different micromolar 
concentrations (ranging from 10, 20 and 30 µM of free ORM and PLGA-ORM and were 
incubated for 48 hour time course. Assay was performed by utilizing an MTS CellTiter96 
Aqueous One Solution. At the end of the indicated time point, 20 µL MTS reagent was 
added to each well and incubated at 37º C for next 2-4 hours. The absorbency was 
measured at 490 nm by using microplate spectra photometer. Experiment was done in 
duplicates and repeated three individual times. Data was compared to vehicle controls. 
 
 
Colony Formation Assay 
 
Caski and SiHa cells were seeded at 500/well in 6 well plates and allowed to 
adhere overnight. Following day, cells were treated with 2.5, 5, 10 µM of free ORM and 
PLGA-ORM and their respective vehicle controls and maintained for another 12-14 days. 
On the 14th day cells were washed with PBS, fixed with ice cold methanol, stained with 
hematoxylin (Thermo Fisher), and washed with water. Colonies that were visible (~50 
cells) were counted manually and compared to the vehicle control ETOH and PLGA 
control to obtain the final result. Experiment was done in duplicate and repeated three 
individual times. 
 
 
Real Time Cell Proliferation Kinetic Assay Using xCELLigence System 
 
The xCELLigence system was used in order to evaluate the effects of PLGA-
ORM on real time cellular proliferation/growth kinetics. xCELLigence system is an 
electrical impedance-based method that provides the real time proliferation 
measurements. For this experiment we used E plate VIEW 16 (ACEA Biosciences) 
which were pre-incubated with 30 µL media for 30 min at 37º C and for the background 
measurement. After 30 min, Caski and SiHa cells were plated at 8×103/chamber in 100 
µL media with drug treatments (20 µM ormeloxifene and PLGA-ORM) in it. Plates were 
incubated in xCELLigence instrument chamber at 37° C with 5% CO2 for real time cell 
proliferation analysis. Experiment was done twice. 
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Mitochondrial Membrane Potential by TMRE 
 
Both Caski and SiHa cells were plated at 200,000/well in 6 well plates and 
allowed to attach overnight. Next day cells were exposed to ORM and PLGA-ORM at 25 
µM concentration along with their vehicle controls. At the indicated time point, cells 
were trypsinized, washed, centrifuged and the final pellet was resuspended in 1 mL PBS 
containing 50 nM TMRE stain. Cells were incubated with TMRE for 30 minutes in the 
dark at room temperature. After the incubation is completed, cells were analyzed by BD 
Accuri C6 flow cytometer under FL2 channel. The experiment was performed three 
times. 
 
 
Statistical Analysis 
 
Statistical analysis was determined by using an unpaired, two tailed student’s t-
test. The results were considered significant if P< 0.05. All graphs were generated using 
GraphPad Prism5 software.  
 
 
Results 
 
 
PLGA-ORM Nanoparticles Internalize in Cervical Cancer Cells  
 
Measuring in vitro cellular internalization of nanoparticle is an essential 
experiment. We used fluorescent microscope and flow cytometer for measuring the 
cellular uptake of PLGA-ORM nanoparticles in cervical cancer calls. The microscopic 
images and flow cytometer data revealed that particles were being taken up by Caski 
(Figure 8-1 and Figure 8-2) and SiHa (Figure 8-3 and Figure 8-4) cell lines in time and 
dose dependent manners. These images suggested that PLGA-ORM was primarily 
located at the cytoplasm of these cells. TEM images data (Figure 8-5, Figure 8-6, 
Figure 8-7 and Figure 8-8) was also consistent with this finding. TEM images revealed 
that PLGA-ORM was internalized in cells just with 3 hours of treatment while no uptake 
was seen in free ORM treated samples. Temperature is an important factor that facilitates 
the uptake of particles. In some cases, particle uptake is energy/temperature dependent. 
Thus, we conducted a flow cytometry study with two different temperatures. The results 
from this experiment showed that at 4º C temperature particle uptake was blocked 
whereas at 37º C, the physiological temperature, the uptake of particles was normal 
(Figure 8-9 and Figure 8-10).  
 
 
PLGA-ORM Nanoparticles Utilizes Endocytosis Pathway for Internalization in 
Cervical Cancer Cells  
 
Endocytosis is the main pathway that nanoparticles use for internalizing into the 
cells. But endocytosis has various different mechanisms/pathways for cellular uptake   
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Figure 8-1. Qualitative representation of cellular uptake of coumarin-6 loaded 
PLGA-ORM nanoparticles in Caski cells. 
 
 
 
 
 
Figure 8-2. Coumarin-6 loaded PLGA-ORM internalization in Caski cells. 
Cells showed an increasing uptake pattern of particles in dose and time dependent 
manner. Results were normalized to the PLGA control particles. Error bars show SEM, 
n=3. *p<0.05.  
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Figure 8-3.  Qualitative representation of cellular uptake of coumarin-6 loaded 
PLGA-ORM nanoparticles in SiHa cells. 
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Figure 8-4. Coumarin-6 loaded PLGA-ORM internalization in SiHa cells. 
Cells showed an increasing uptake pattern of particles in dose and time dependent 
manner. Results were normalized to the PLGA control particles. Error bars show SEM, 
n=3. *p<0.05. 
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Figure 8-5. Cellular internalization of free ORM in Caski cells showed by TEM. 
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Figure 8-6. Cellular internalization of PLGA-ORM in Caski cells showed by 
TEM. 
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Figure 8-7. Cellular internalization of free ORM in SiHa cells showed by TEM. 
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Figure 8-8. Cellular internalization of PLGA-ORM in SiHa cells showed by TEM. 
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Figure 8-9. Internalization of Coumarin-6 loaded PLGA-ORM is energy 
dependent in Caski cells. 
Cells showed blocked or inhibited uptake of particles when incubated at 4º C 
temperature. Results were normalized to the PLGA control particles. Error bars show 
SEM, n=3. *p<0.05. 
 
  
  
100 
 
 
Figure 8-10. Internalization of Coumarin-6 loaded PLGA-ORM is energy 
dependent in SiHa cells. 
Cells showed blocked or inhibited uptake of particles when incubated at 4º C 
temperature. Results were normalized to the PLGA control particles. Error bars show 
SEM, n=3. *p<0.05. 
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(Figure 8-11) [197]. Therefore to determine the uptake mechanism of PLGA-ORM 
nanoparticles, we treated Caski and SiHa cells with different endocytosis pathway 
inhibitors and performed flow cytometery. Data from this experiment suggested that 
particles mainly utilized the lipid raft, caveolae and micropinocytosis pathways to get 
into the Caski cells (Figure 8-12). While in SiHa cells particles preferred lipid raft, 
clatherin, caveolae and micropinocytosis pathways for their internalization (Figure 8-13). 
 
 
PLGA-ORM Decreases Cellular Viability, Clonogenic Potential and Mitochondrial 
Membrane Potential of Cervical Cancer Cells 
 
In order to elaborate anti-cancerous properties of PLGA-ORM, we assessed an 
MTS assay for 48 hours. The results showed a marked decrease in cellular viability of 
both cell lines (Figure 8-14 and Figure 8-15) when compared to free ORM. When we 
performed the colony formation assay for the long term treatment capability of PLGA-
ORM, the results were even better. PLGA-ORM had an inhibitory effect on clonogenic 
potential of both Caski and SiHa cells in comparison to free ORM (Figure 8-16, Figure 
8-17, Figure 8-18 and Figure 8-19). Interestingly, PLGA-ORM had lower number of 
colonies than free ORM even at the lowest concentration of 2.5 µM. Real time growth 
kinetics by the xCELLigence system also supported these findings (Figure 8-20 and 
Figure 8-21). We also performed a Flow cytometry experiment to analyze the ability of 
PLGA-ORM to induce apoptosis. We used TMRE stain to detect the depolarized 
mitochondria which is an indication of apoptosis induction. Our flow cytometer data 
revealed that PLGA-ORM significantly reduced the mitochondrial membrane potential of 
both Caski and SiHa cells when compared to free ORM (Figure 8-22 and Figure 8-23). 
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Figure 8-11. Representation of different endocytosis pathway and their inhibitors. 
Modified with permission. Mayor, S. and R.E. Pagano, Pathways of clathrin-independent 
endocytosis. Nature reviews Molecular cell biology, 2007. 8(8): p. 603-612. 
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Figure 8-12. PLGA-ORM nanoparticles entered Caski cells using endocytosis 
pathway. 
Cellular uptake of formulation after using different endocytosis pathway inhibitors. 
Results were normalized to the PLGA-ORM C6 particles. Error bars show SEM, n=3. 
*p<0.05. 
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Figure 8-13. PLGA-ORM nanoparticles entered SiHa cells using endocytosis 
pathway. 
Cellular uptake of formulation after using different endocytosis pathway inhibitors. 
Results were normalized to the PLGA-ORM C6 particles. Error bars show SEM, n=3. 
*p<0.05. 
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Figure 8-14. PLGA-ORM decreased cellular proliferation of Caski cells. 
Cells were treated with ormeloxifene and PLGA-ORM (10, 20 and 30 µM) for 48 hrs, 
MTS method was used to determine proliferation, and absorbance was measured at 490 
nm. Results were normalized to the vehicle controls (ETOH and PLGA) and free 
ormeloxifene. Error bars show SEM, n=3. *p<0.05. 
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Figure 8-15. PLGA-ORM decreased cellular proliferation of SiHa cells. 
Cells were treated with ormeloxifene and PLGA-ORM (10, 20 and 30 µM) for 48 hrs, 
MTS method was used to determine proliferation, and absorbance was measured at 490 
nm. Results were normalized to the vehicle controls (ETOH and PLGA) and free 
ormeloxifene. Error bars show SEM, n=3. *p<0.05. 
 
 
 
 
 
Figure 8-16. PLGA-ORM decreased colony forming ability of Caski cells. 
Cells were treated with ormeloxifene and PLGA-ORM (2.5, 5 and 10 µM) for 14 days. 
Images were taken at 200X using a phase contrast microscope.  
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Figure 8-17. Bar graph showing that PLGA-ORM decreased colony forming 
ability of Caski cells. 
Cells were treated with ormeloxifene and PLGA-ORM (2.5, 5 and 10 µM) for 14 days. 
Results were normalized to the vehicle controls (ETOH and PLGA) and free 
ormeloxifene. Error bars show SEM, n=3. *p<0.05. 
 
 
 
 
 
Figure 8-18. PLGA-ORM decreased colony forming ability of SiHa cells. 
Cells were treated with ormeloxifene and PLGA-ORM (2.5, 5 and 10 µM) for 14 days. 
Images were taken at 200X using a phase contrast microscope.  
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Figure 8-19. Bar graph showing that PLGA-ORM decreased colony forming 
ability of SiHa cells. 
Cells were treated with ormeloxifene and PLGA-ORM (2.5, 5 and 10 µM) for 14 days. 
Results were normalized to the vehicle controls (ETOH and PLGA) and free 
ormeloxifene. Error bars show SEM, n=3. *p<0.05. 
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Figure 8-20. PLGA-ORM inhibited growth of Caski cells in real time. 
Cells were exposed to ormeloxifene and PLGA-ORM treatments and then measured for 
real time growth kinetics. 
 
 
 
 
 
Figure 8-21. PLGA-ORM inhibited growth of SiHa cells in real time. 
Cells were exposed to ormeloxifene and PLGA-ORM treatments and then measured for 
real time growth kinetics. 
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Figure 8-22. PLGA-ORM reduced mitochondrial membrane potential of Caski 
cells as measured by TMRE stain using flow cytometer. 
Cells were treated with ormeloxifene and PLGA-ORM for 24 hours. Results were 
normalized to the vehicle controls (ETOH and PLGA) and free ormeloxifene. Error bars 
show SEM, n=3. *p<0.05. 
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Figure 8-23. PLGA-ORM reduced mitochondrial membrane potential of SiHa cells 
as measured by TMRE stain using flow cytometer. 
Cells were treated with ormeloxifene and PLGA-ORM for 24 hours. Results were 
normalized to the vehicle controls (ETOH and PLGA) and free ormeloxifene. Error bars 
show SEM, n=3. *p<0.05. 
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CHAPTER 9.    IN VIVO VALIDATION OF ANTI-CANCEROUS/TUMOROUS 
FUNCTION OF ORMELOXIFENE AND PLGA-ORM  
 
 
Materials and Methods 
 
 
 In vivo Orthotopic Tumoral Study 
  
In order to study the anti-tumoral properties of ormeloxifene and PLGA-ORM, 
we developed an orthotopic mice model for cervical cancer (Figure 9-1). 4-6 weeks-old 
nu/nu female mice were purchased from Jackson laboratories and maintained in a 
pathogen-free environment. HPV positive Caski cervical cancer cells (5X106 per mouse) 
were suspended in PBS and matrigel (BD Bioscience) at a 1:1 ratio. Cell suspension 
(5X106 cells in 100 µL) was injected orthotopically direct to the cervix of each mouse. 
Mice were monitored for the tumor development and once tumor reached the size of 
around 100 mm3, we started the drug treatment. Mice were treated with free ORM, 
PLGA-ORM, PBS and PLGA NPs (vehicle controls) at the concentration of 100 
µg/mouse (chosen based upon our previous studies in the lab) intraperitoneally (i.p.) for 
the systemic therapy. Tumor volumes were measured by using a digital vernier caliper 
and calculated using the formula of tumor volume (mm3) = π/6 x L x W x H measured bi-
dimensionally, and survival was noted up to day 40. Mice survival was analyzed by 
Kaplan Meir analysis. Mice were sacrificed during the experiment if tumor 
volume/weight reached more than 10% of body weight (1.5-2.0 gram) or if mice lost 
more than 10% of their total body weight. On day 40, mice were euthanized and tumors 
were observed and dissected. 
 
 
Statistical Analysis 
 
Statistical analysis was determined by using an unpaired, two tailed student’s t-
test. The results were considered significant if P< 0.05. All graphs were generated using 
GraphPad Prism5 software.  
 
 
Results 
 
PLGA-ORM nanoparticles inhibited cervical cancer tumorigenesis in orthotopic 
mice model. It is imperative to test PLGA-ORM in vivo after seeing its anti-cancerous 
prosperities in in vitro system. In order to evaluate anti-tumorous efficacy of PLGA-
ORM, we generated an orthotopic cervical cancer mouse model using female nude mice. 
For this mouse model development, we used HPV positive Caski cervical cancer cells 
and injected directly into the cervix of these female nude mice. Mice started developing 
tumors within 15-20 days. Once the tumor size was around 100 mm3, free ORM and 
PLGA-ORM along with their respective controls PBS and PLGA were administered by  
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Figure 9-1. Schematic of in vivo study. 
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intra-peritoneal injections (Figure 9-1). The study was terminated when the tumor size 
reached around 1000 mm3, at the termination, mice were euthanized and tumors were 
dissected from all groups (Figure 9-2). During the entire study tumor size/volume was 
measured. ORM and PLGA-ORM significantly decreased the tumor volume when 
compared to their respective controls (Figure 9.3). We also measured the tumor weight 
after dissection and results suggested that ORM and PLGA-ORM reduced the tumor 
weight markedly when compared to their controls (Figure 9-4). Interestingly, PLGA-
ORM had more inhibitory effect on tumor size and weight than that observed with free 
ORM (Figure 9-3 and Figure 9-4). After further validation, it was observed that ORM 
and PLGA-ORM also increased the overall mice survival rate (Figure 9-5). 
 
 
 
 
 
 
Figure 9-2. Images represent mice from different treatment groups and their 
dissected tumors 
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Figure 9-3. PLGA-ORM inhibited tumor growth of cervical cancer orthotopic 
mice model. 
Average tumor volume of ormeloxifene and PLGA-ORM treated mice. Error bars show 
SEM, n=6. 
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Figure 9-4. Weight measurement from the tumors dissected from mice. 
ORM and PLGA-ORM significantly reduced the tumor weight when compared to their 
respective vehicle controls PBS and PLGA, Error bars show SEM, n=6. *p<0.05. 
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Figure 9-5. Percent survival curve for ORM and PLGA-ORM treated mice. 
PLGA-ORM (Red Line) showed the 100% survival over other groups. 
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CHAPTER 10.    DISCUSSION* 
 
 
Despite of having various preventative modalities including vaccines and 
screening, advanced stage cervical cancer is a deadly malignancy in women. Advanced 
stages of cervical cancer remain untreatable as a result of many modulations at the 
cellular and molecular level. Cells become more motile/ invasive and show resistance 
towards chemo and radiotherapy. Thus, newer therapeutic modalities are highly desirable 
that may provide protection against metastasis and chemo/radio-resistance. In the modern 
research world, repurposing of already in use molecules has become a new attraction. 
Considering the potential of repurposing a drug that is in use already, we investigated the 
therapeutic potential of ormeloxifene in this study. Ormeloxifene has been used for its 
birth control purposes for more than last two decades in India. Ormeloxifene targets high 
proliferative decidual cells in the endometrium and it is reported safe to use. Recently, 
studies from other groups as well as our lab have demonstrated that ormeloxifene has 
anti-cancerous activities against breast, head and neck, ovarian, pancreatic and leukemia 
cancers.  
 
Uncontrolled cell proliferation/ growth and inability to have programmed cell 
death are the major causes of cancer development. In this study we show that 
ormeloxifene decreases cellular proliferation of four different cells, both HPV positive 
and negative with a short term (48 hrs) treatment of ormeloxifene at micro-molar 
concentrations confirmed by MTS assay. Results from xCELLigence real time growth 
kinetic assay are also consistent with MTS data findings. Ormeloxifene also inhibits the 
clonogenic potential of all four cell lines with a long term treatment of about 14/15 days. 
Results are consistent with previous work on ormeloxifene’s anti-proliferative potential. 
Upon the drug treatment, cells exhibit clear signs of apoptosis. Ormeloxifene treatment 
alters the morphology of Caski and SiHa cells and shows the apoptosis like signs such as 
membrane blebbing, cell shrinkage and round of shape. Apoptosis is a major event that 
occurs in response to many anti-cancer drugs. Apoptosis consists of two different 
pathways, namely extrinsic and intrinsic. Intrinsic apoptotic death cascade involves the 
depolarization of mitochondrial membrane as a first event of the cascade that further 
leads to activation of Caspase and results in PARP cleavage. Ormeloxifene treatment for 
24 hours affects the mitochondrial membrane depolarization as confirmed by decreased 
mitochondrial membrane potential assessed by TMRE staining through fluorescent 
microscopy and flow cytometer. Annexin V-7AAD staining is another method to detect 
the apoptotic cell population. Ormeloxifene treatment for 24 hours results in increased 
apoptotic population of Caski and SiHa cells which indicates that ormeloxifene has a 
potential to become anti-proliferative/growth molecule for cervical cancer. 
 
Excessive cell cycle progression is a key property of cancerous cells and 
controlled by many activated cyclins and their dependent kinase. Ormeloxifene treatment 
 
----------------------------- 
* Adapted with permission. Khan, S., et al., Nanoparticle formulation of ormeloxifene for 
pancreatic cancer. Biomaterials, 2015. 53: p. 731-743.  
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plays an inhibitory role in cell cycle progression of Caski and SiHa cells. It arrests cell 
cycle in both cell lines at G1-S transition and decreases the expression of Cyclin E and its 
dependent kinase CDk2. Cyclin E and cdk2 help cells to progress from G1 phase to S 
phase. PI3K-Akt pathways play an important role in cell growth and cell cycle 
progression. In accordance with previous findings, we show that ormeloxifene 
downregulates the PI3K-Akt pathway in cervical cancer cells as shown by decreased 
expression levels of PI3K and Akt, and increased phosphorylation of Akt. Ormeloxifene 
further decreases the downstream target of PI3K-Akt pathway, p21, a known inhibitor of 
cell cycle progression. Cancer cells show enhanced motility and invasion which helps 
cancer cells migrate from one organ to another and this is how cancer spreads. Molecules 
that inhibit migratory and invasive property of cancer cells are the strong candidates for 
having anti-cancerous properties. We utilized various techniques including agarose bead 
assay, Boyden chamber migration, invasion assay and real time migration/invasion by 
xCELLigence to confirm ormeloxifene’s effect on motility of Caski and SiHa cell lines. 
Results reveal that cells become less motile and invasive with ormeloxifene treatment for 
24 hours. 
 
Persistent HPV infection is required for the progression of cervical cancer so we 
intended to assess ormeloxifene’s effect on HPV E6 and E7 expression. Ormeloxifene 
successfully inhibits the mRNA levels of HPV E6 and E7 with 6 hours of treatment; the 
downregulation also continued to the translational levels as ormeloxifene decreases the 
expression of HPV E6 and E7 oncoproteins with 24 hours treatment. HPV E6 and E7 
deregulate the cell cycle by inactivating tumor suppressor proteins p53, Rb and PTPN13; 
interestingly, ormeloxifene unregulated the expression of these three proteins. These 
findings suggest that ormeloxifene not only decreases the oncogenic signaling but also 
increases the tumor suppressing signaling, thus, demonstrates potent anti-HPV properties 
in cervical cancer cells.  
 
Ormeloxifene also sensitized Caski cervical cancer cells to radiation. Data 
showed that pre-treatment of ormeloxifene (24 hours prior to radiation exposure for 
proliferation and 6 hours prior for colony formation) had better and improved growth 
inhibitory effects on cells when compared with ormeloxifene and radiation alone. 
 
Ormeloxifene is a synthetic molecule which is widely used as an oral 
contraceptive in humans and exhibits potent anti-cancer activity by targeting the key 
underlying oncogenic molecular mechanisms [198-205]. Hence, our aim of this study 
was to enhance ORM delivery at the tumor site for improved therapeutic effects/index for 
cervical cancer treatment. To this end, we have developed an efficient PLGA NP (PLGA-
ORM NP) based delivery system, to enhance the anti-cancer efficiency of ORM at the 
tumor site. In the present study, an optimized PLGA-ORM 20 NP formulation was made 
with an average particle size of 101.4 ± 1.5 nm with 84.96 ± 4.75% drug-loading 
capacity. This formulation provides good suspension while maintaining long-term 
stability, up to 6 months. From the results of FT-IR, DSC, and TGA, it is evident that 
PLGA, PVA, and PLL polymers form undefined structure in PLGA-ORM NPs, which 
allow for the controlled release in cancer cells. We observed that PLGA-ORM NPs 
delivered a higher payload of ORM in cervical cancer cells which was correlated with the 
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increased cytotoxicity in cervical cancer cells. Elucidating the internalization mechanisms 
could provide crucial insights into engineering novel cancer therapeutics yielding more 
potent and selective nanoformulations. The uptake and internalization of PLGA-ORM 
NPs follow an endocytotic pathway, which is consistent with most of the conventional 
nanoformulations [206]. 
 
This study with PLGA-ORM NPs demonstrates enhanced anti-cancer effects over 
free ORM against four different cervical cancer cell lines in proliferation and clonogenic 
potential assays. Additionally, PLGA-ORM induces apoptosis in cervical cancer cells. 
From a clinical translational point of view, achieving the highest drug loading is more 
favorable for clinical use to improve pharmacokinetic profiles. Therefore, we have 
engineered an optimized PLGA-ORM20 NP formulation with higher loading capacity. 
The higher drug loading not only minimizes (i) processing, (ii) overall raw materials, and 
(iii) non-active ingredients for generating the formulation, but efficiently delivers an 
equivalent dose of ORM. Overall, in this proof-of-concept study, we have demonstrated 
that PLGA-ORM20 NP formulation is highly suitable to deliver ORM more efficiently at 
the tumor site to induce superior anti-cancer activity. 
 
After discussing all the outcomes of this work, it can be said that the central 
hypothesis and the questions asked, were completely justified in this dissertation work. 
This dissertation work provides an insight on an upcoming repurposed molecule that has 
great potential to become an anti-cervical cancer agent. This work holds substantial 
promises for future, thus, needs to be continued in order to further understand the 
underlying mechanisms of these results. Our data indicated that PI3K-Akt which is one of 
the main stream pathways involved in cervical cancer carcinogenesis is inhibited by 
ormeloxifene so further work is required to establish this pathway as the mechanism of 
action for ormeloxifene in cervical cancer. Our combination therapy data with 
ormeloxifene and radiation on proliferation/growth studies also exhibited excellent 
outcomes. This work certainly needs to be carried forward in future where it can be tested 
in vitro and in vivo to investigate a combination therapy for cervical cancer management. 
Also, the in vitro and in vivo studies with nanoformulation of ormeloxifene revealed its 
future commercial prospective. Summing up, this dissertation work holds a considerable 
potential to be extended in future and to be continued in translational settings. 
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